Costs and unintended consequences of drug control policies. by Bretteville-Jensen, Anne Line et al.
COSTS AND 
UNINTENDED 
CONSEQUENCES 
OF DRUG CONTROL 
POLICIES
Authors: 
Anne Line Bretteville-Jensen 
Sania Mikulic 
Pavel Bem 
Fivos Papamalis 
Yossi Harel-Fisch 
Janusz Sieroslawski 
Fatima Trigueiros 
Laura Piscociu 
Sergey Tsarev 
Peyman Altan 
Claudia Costa Storti
Authors: 
Anne Line Bretteville-Jensen (Norway) 
Chair of the expert group 
Norwegian Institute of Public Health
Sania Mikulic (Croatia) 
Office for combating drugs abuse Government 
of the Republic of Croatia
Pavel Bem (Czech Republic) 
Charles University Prague
Fivos Papamalis (Greece) 
Advisor to the Greek National Drug Coordinator
Yossi Harel-Fisch (Israel) 
Israel Anti Drug Authority 
Janusz Sieroslawski (Poland) 
Institute of Psychiatry & Neurology
Fatima Trigueiros (Portugal) 
General Directorate for Interventions on Addictive 
Behaviours and Dependencies
Laura Piscociu (Romania) 
Romanian National Anti-Drug Agency
Sergey Tsarev (Russian Federation) 
State Medical Institution “Chapaevsk Narkology Hospital”
Peyman Altan (Turkey) 
Turkish Public Health Institution, Ministry of Health
Claudia Costa Storti (EMCDDA)
COSTS AND 
UNINTENDED 
CONSEQUENCES 
OF DRUG CONTROL 
POLICIES
Council of Europe
Report by the expert group on possible adverse effects 
and associated costs of drug control policies
The opinions expressed in this work are the responsibility 
of the authors and do not necessarily reflect the official 
policy of the Council of Europe or the Pompidou Group. 
All requests concerning the reproduction or 
translation of all or part of this document should 
be addressed to the Directorate of Communication 
(F-67075 Strasbourg Cedex or publishing@coe.int). 
All other correspondence concerning this document 
should be addressed to the Pompidou Group.
Cover and layout: Documents and Publications 
Production Department (SPDP), Council of Europe
This publication has not been copy-
edited by the SPDP Editorial Unit to correct 
typographical and grammatical errors.
© Council of Europe, November 2017 
Printed at the Council of Europe
 ► Page 3
Contents
FOREWORD 5
ACKNOWLEDGEMENTS 6
INTRODUCTION 7
Public expenditure and evaluation of drug policies 8
Unintended consequences of drug control policies 9
The aims and outline of the report 9
PUBLIC EXPENDITURE ON DRUG CONTROL POLICIES 11
Introduction 11
Defining concepts 12
Empirical estimates of demand and supply policy expenditure 12
Steps in cost estimation and analysis 13
Examples of sectorial models 17
Examples of national studies 18
International estimates and databases used to model drug-related public expenditure 20
Conclusions 21
Recommendations 21
UNINTENDED CONSEQUENCES OF DRUG CONTROL POLICIES 23
Health effects from restricted availability of controlled medicines 24
Health effects due to drug prohibition 27
Health effects resulting from enforcement actions 31
Effects of high profit margins and price levels of illegal drugs 36
Effects resulting from stigmatization 39
Effects of criminal records and imprisonment for drug offences 41
DISCUSSION 45
Improving and employing public expenditure estimates for drug control policies 45
Acknowledged and taking into account unintended consequences 46
Conclusion 47
APPENDIX 1 – AVAILABLE DATABASES AND POTENTIAL INDICATORS FOR DRUG-RELATED PUBLIC 
EXPENDITURES 49
APPENDIX 2 – THE INTERNATIONAL CLASSIFICATION OF THE FUNCTIONS OF GOVERNMENT (COFOG) 52
APPENDIX 3 – SUMMARY TABLES: DATA FROM INTERNATIONAL DATABASES 53
ACRONYMS 58
TABLE REFERENCES 58
REFERENCES 59

 ► Page 5
Foreword
E
valuation is an integral part of a good gover-
nance approach to public policy. This principle 
applies equally to the component of drug policy 
designed to counter the availability of and access to 
illicit drugs. Estimation or full costing of drug-related 
public investment – including both direct expendi-
ture and also indirect costs and impact on public 
resources – should therefore be a key objective of 
any evaluation. 
To evaluate and improve drug policy, it is imperative to 
know and take note of all possible effects of different 
interventions and actions. All policies, regardless of 
purpose or intention, come with a risk of unintended 
consequences. 
Public expenditure estimates can be used as a tool for 
assessing whether the expected or desired results of 
the policy in question are actually reflected in action, 
and they constitute a necessary tool for implement-
ing thorough policy evaluations. Public expenditure 
studies should mirror all relevant activities and policy 
approaches and may be particularly appropriate in 
times of austerity.
Accurate estimates of public spending will help pol-
icymakers plan relevant interventions and allocate 
necessary funds to authorities in charge of specific 
aspects of the policy’s implementation. A thorough 
assessment of drug policy expenditures will also con-
tribute to improved transparency and accountability 
of public institutions. 
This publication brings together the findings of wider 
study conducted by the Pompidou Group in coopera-
tion with the EMCDDA seeking to identify the unin-
tended effects and associated costs of drug control 
policies. The aim of this publication is threefold. First, 
increase international awareness about the impor-
tance of estimating public expenditure on supply 
reduction initiatives. Second, stress the importance 
of harmonizing definitions and increasing availability, 
comparability and reliability of data as well as methods 
for sound estimates. Third, contribute to developing 
sound estimation practices to obtain accurate, com-
plete and reliable drug policy evaluations.
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Chapter 1
Introduction
T
here is broad consensus that one overall aim of 
drug policy is to advance the health and welfare 
of mankind and reduce the individual and public 
health-related, social and safety problems resulting 
from the abuse of narcotic drugs and psychotropic 
substances (1). At the UN General assembly in April 
2016, Heads of State and Governments reaffirmed 
their determination to prevent and treat the abuse of 
such substances and prevent and counter their illicit 
cultivation, production, manufacturing and traffick-
ing. Despite this general understanding, the design 
and content of national drug policies vary to a large 
extent. The variation partly reflects differences in the 
nature of national drug problems and the resources 
allocated to this policy field, but also reflects ideo-
logical differences in how governments respond to 
drug problems. 
In line with much of the academic literature (2), 
this report uses the term “drug policy” as to include 
governmental policies on prevention, enforcement, 
treatment, harm reduction and social reintegration. 
The policies include laws and programs intended to 
influence drug use and its consequences for users 
and society. National drug control policy constitutes 
one subset of drug policies and is based on three 
internationally agreed conventions, namely the 
1961 Single Convention on Narcotic Drugs; the 1971 
Convention on Psychotropic Substances; and the 
1988 United Nations Convention Against Illicit Traffic 
in Narcotic Drugs. National legislations may introduce 
stricter domestic legislation than that demanded by 
the Conventions but they should not bring in more 
lenient legislation (3). Signing countries are obligated 
to make drug supply, i.e. production, sale, transport 
and distribution of drugs for non-medical purposes, 
a criminal act. The drug conventions further oblige 
states to ensure that possession of drugs, even in small 
quantities, shall be a punishable offence, though not 
necessarily a criminal offence. The Conventions offer 
alternatives to conviction or punishment, including 
treatment, education, aftercare, rehabilitation and 
social reintegration (4). 
The overarching objective of supply reduction policy 
is a measurable reduction of the availability of illicit 
drugs and of associated crime. Elements central to 
achieving this goal include disruption of illicit drug 
trafficking, dismantling of organised crime groups 
that are involved in drug production and trafficking, 
efficient use of the criminal justice system, effec-
tive intelligence-led law enforcement and increased 
intelligence sharing, and international collaboration 
to address large-scale, cross-border and organised 
drug-related crime (5). While the conventions treat 
the listed drugs similarly, national drug laws and 
enforcement practice often distinguish between types 
of drugs. The use, possession, sale and production 
of cannabis, for example, is in most countries regu-
lated and enforced very differently from substances 
like amphetamines, cocaine or heroin. The intended 
effects of these legal responses, such as sentencing 
a drug dealer to prison, are twofold: first, to punish 
the offender and second, to deter the offender and 
others from committing similar crimes (the principles 
of punishment and deterrence). 
Although supply-reducing interventions often consti-
tute the dominant part of drug control policy, enforce-
ment procedures against users often gain more public 
attention and disapproval, with criticism increasing 
in recent years. More and more often, loud voices are 
questioning the efficiency of drug control measures 
and some even claim that they are counterproduc-
tive (see e.g. Global commission of drugs, 2011 (6)). 
Unequal enforcement and disproportionate response 
have led to criticism of drug control efforts. The use of 
the death penalty in some countries is one extreme 
example of this, but less extreme cases in Europe have 
been a topic of discussion. The increased criticism of 
drug control efforts is one contributing factor to the 
recent changes introduced in drug regulations in 
many countries and jurisdictions. 
The decriminalisation of drugs in Portugal and the 
Czech Republic, the recent legalisation of cannabis 
in eight US states, the state regulation of cannabis in 
Uruguay and the foreseen depenalization of cannabis 
in Canada are illustrations of a more liberal trend in 
drug control policies. The call for further humanisa-
tion and revision of drug control policies must be 
viewed in light of the increased focus on its adverse 
consequences. 
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Drug control policy has both domestic and interna-
tional dimensions. Nationally, it includes factors such 
as (7): development of judicial frameworks; enforce-
ment of anti-drug laws; eradication of drug produc-
tion and cultivation; control of precursor chemicals; 
strengthening public institutions to avoid corruption 
and guarantee governability; customs inspections 
of commerce and persons entering the country and 
screening for drugs in prisons. Internationally, drug 
control policy includes elements like: development 
of judicial frameworks for international cooperation; 
creation of tools for international law enforcement 
cooperation; coordinated international investigations; 
control of precursor chemicals; anti-money-laundering 
initiatives; drug-crop substitution and eradication and 
initiatives against drug-related corruption, terrorism 
and human trafficking.
Drug control measures may be grouped according 
to whether they are targeting drug users or drug 
producers, traffickers and suppliers. In both cases, 
governments have obligations under international 
and national legal instruments to safeguard funda-
mental standards of human rights and the rule of law, 
which apply to drug offenders. These obligations are 
described by the Council of Europe (CoE) Convention 
for the Protection of Human Rights and Fundamental 
Freedoms, which guarantees (8):
► The right to life
► The right to protection of health
► The right to non-discrimination 
► The prohibition of inhuman or degrading 
treatment 
In addition, the rights are stated in: 
Article 38.1 of the UN Single Convention on Narcotic 
Drugs, which requires States to pay special attention 
to and take all measures for the prevention of abuse 
of drugs and for the early identification, treatment, 
education, after-care, rehabilitation and social rein-
tegration of persons dependent on drugs; 
Article 25 of the Universal Declaration of Human 
Rights (UDHR), which guarantees everyone the right 
to a standard of living adequate for his health and 
well-being, including medical care and necessary 
social services; 
Article 12 of the UN International Covenant on 
Economic, Social and Cultural Rights (ICESCR), which 
recognizes the right of everyone to the enjoyment 
of the highest attainable standard of physical and 
mental health; and requires States to assure medical 
service and medical attention is available equitably 
to all in need.
Article 11 of the CoE European Social Charter (revised), 
which provides for the right to protection of health 
and stipulates the effective exercise of the right to 
protection of health. 
Public expenditure and 
evaluation of drug policies
Drug policy evaluation is an integral part of the 
approach to counter illicit drugs (9). Estimation of 
drug-related public expenditure can be seen as a first 
step in this direction. Public expenditure estimates aim 
to calculate the amount of resources spent, or required, 
to implement targeted interventions in a particular 
policy field. These estimates may reveal to what extent 
policy intentions are reflected in relevant budgets and 
are conditioned by the size and characteristics of the 
drug phenomenon. Most European countries have 
a national drug policy presented in a drug strategy 
document (5). National drug strategies attempt to 
target both drug demand and drug supply reduction, 
though these two sectors do often not receive an 
equal share of resources and attention. Instead, the 
allocation of resources depends on country specific 
priorities and aims for different drug policy sectors, 
as well as on the relative price of implementing each 
activity in a cost-effective manner. 
Accurate estimates of public spending will help pol-
icymakers plan relevant interventions and allocate 
necessary funds to authorities in charge of policy 
implementation. A thorough assessment of drug 
policy expenditures will also contribute to improved 
transparency and accountability of public institutions. 
Estimates may provide information on factors such 
as the relative importance of demand and supply 
expenditures and enable cross-country comparisons 
of the level and composition of spending (10). Sound 
planning, improved knowledge of the resources allo-
cated to this policy field, and cost-effective resource 
allocation are particularly necessary in times of eco-
nomic downturn when fewer resources are available. 
To optimize resource allocation to this policy field, one 
should ideally conduct a full cost-benefit analysis. A 
cost-benefit analysis systematically compares all costs 
and benefits of one particular policy area or project 
to determine whether there is a positive net benefit 
(i.e. whether benefits outweigh the costs). This type of 
analysis can also compare alternative policy options 
and evaluate the effectiveness of separate parts of a 
comprehensive policy. For the drug control sector, a 
cost-benefit analysis should explicitly take all costs, 
including unintended adverse effects of the policy, 
into account when evaluating whether the policy 
provided a net benefit to society. Unfortunately, a 
regular cost-benefit analysis is currently not attainable 
as the quantification of both benefits and costs of drug 
control policies are underdeveloped. Still, a better 
understanding of the different elements involved is 
possible and useful. This report takes the first step 
towards such a systematic analysis by examining the 
public expenditure and the unintended consequences 
of the drug control policy. 
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We define drug control costs to include all kinds of 
public expenditure on efforts aiming at reducing 
drug use and availability through enforcing the drug 
laws. Thus, drug control costs comprise government 
expenditures on public order and safety, such as bud-
getary expenses for police, customs, judicial system 
and prisons. The vast majority of these resources are 
spent on enforcement against producers and dealers, 
but expenditures also include legal action against drug 
users in some countries. It should be noted that the 
term “drug control costs” will be used interchangeably 
with “supply reduction costs” in this report. This is con-
sistent with terminology used by other international 
organisations such as the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA). 
Limited data availability is often a challenge when 
conducting drug-related public expenditure analysis. 
Many countries do not have separate budgets for 
drug-related expenditures, as they are embedded 
in broader budget categories. Often, more than one 
sector is involved and expenditures may be found at 
different administrative levels (central, regional, local). 
Chapter 2 presents examples of expenditure analyses 
and provides suggestions for how to improve data 
collection and estimates.
Unintended consequences 
of drug control policies
To evaluate and improve drug policy, it is imperative to 
know and take note of all possible effects of different 
interventions and actions. All policies, regardless of 
purpose or intention, come with a risk of unintended 
consequences. Unintended consequences can be 
defined as consequences that are not deliberate or 
intentional; they are not the targeted effects of any 
given action. This does not necessarily imply, how-
ever, that these consequences are unexpected – on 
the contrary, their occurrence may in some cases 
be considered very likely. For instance, a ban on the 
production and sale of listed substances carries a 
high risk of the appearance of an illegal drug market. 
Unintended consequences will vary substantially from 
country to country depending on national drug leg-
islation and its de facto implementation. One should 
bear in mind, however, that even the most liberal 
control regimes will produce unintended effects. If 
all drugs were freely available and no control mea-
sures were implemented, a substantial non-intended 
burden on society and non-users would still result as 
a consequence of the amount and type of drugs con-
sumed and modes of drug-taking. Further, legal but 
regulated drugs like alcohol and tobacco also result 
in control costs and consequences, both intended 
and unintended. 
Unintended consequences may further vary according 
to the social/economic context, type of substance, 
individual characteristics and time period. Some of 
these consequences relate to drug market partici-
pants (drug users and suppliers), while others relate 
to non-participants and to society in general. Often-
mentioned unintended consequences affecting drug 
offenders include stigmatization, social exclusion, 
negative effects of imprisonment, reduced educational 
and labour market opportunities, disconnection to 
work life and travel restrictions (visa denial), while 
non-participants suffer consequences such as limited 
access to essential medicines for medical and scientific 
purposes. Further, unintended societal consequences 
can include factors such as the emergence of orga-
nized crime and human trafficking or a general risk of 
reduced public safety due to illegal methods of drug 
financing. Some producing countries like Mexico and 
Colombia have experienced extreme violence and 
thousands of deaths, while public health, security 
and safety have been negatively affected in many 
European countries (11). 
Although most unintended consequences of drug 
control policy negatively influence those affected, 
there may also be some positive unintended con-
sequences. For instance, imprisoned drug offenders 
are likely to reduce their risk-behaviour and drug use 
while incarcerated, and they may get access to health 
care, education and treatment in prison. Local drug 
enforcement may also reduce other types of crime, 
increasing safety in certain neighbourhoods. Positive, 
as well as negative unintended consequences should 
be adequately accounted for in policy making. 
The aims and outline of the report
This report aims to define and identify costs and unin-
tended negative effects of drug control policies, borne 
by individuals and society. We do this to improve the 
knowledge base and better enable policymakers to 
make informed choices in this area. Improved knowl-
edge with regard to the resources that are allocated 
to this policy field will help planning and strategic 
thinking, particularly appropriate in times of austerity. 
As there is no way to completely avoid unintended 
consequences, it is important to adequately take them 
into account when deciding on aims and measures 
for handling the drug phenomenon. Furthermore, we 
suggest possible interventions to reduce the impact of 
the identified consequences. There are interventions 
available that may reduce the adverse and unintended 
effects of drug control policy, regardless of what reg-
ulatory regime is implemented. 
Some central concepts of drug control policy are 
defined and discussed in Chapter 1. Chapter 2 provides 
guidelines for how to collect relevant cost informa-
tion and proposes a common set of definitions and 
methods to be used for public expenditure assessment 
and evaluation. Further, we present compiled national 
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information of levels and compositions of drug-related 
public expenditure, which show that most countries 
seem to spend more on supply reducing than on 
demand reducing efforts. Chapter 3 presents our 
analysis of unintended consequences. Although we, 
of course, acknowledge that defining and measuring 
intended effects is an important task for any policy 
evaluation, the focus of this report is the unintended 
negative ones. These unintended consequences 
are split into health and non-health effects and are 
related to the bearers of these consequences (users 
and non-users of drugs). The chapter also offers a list 
of possible interventions that may reduce unintended 
consequences. Chapter 4 discusses our findings and 
suggests a way forward.
Figure 1 illustrates the outline of the report. 
Costs = Public expenditures
Drug control policy
Intended
Effects
Health
Unintended
Non-health
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Chapter 2
Public expenditure 
on drug control policies
Introduction
The aim of this chapter is threefold: First, to increase 
international awareness concerning the importance 
of estimating public expenditure on supply reduc-
tion initiatives. Second, to raise public awareness 
of the need to agree upon harmonising definitions 
and increasing the availability, comparability and 
reliability of data, as well as methods for producing 
sound estimates. Third, to contribute to developing 
national and international estimation practices with 
a view to obtaining accurate, complete, reliable and 
comparable drug policy evaluations.
As mentioned in Chapter 1, the overarching objective 
of drug control policy is a measurable reduction in 
the availability and accessibility of illicit drugs. Drug 
control initiatives comprise the whole system of laws, 
regulatory measures, courses of action and funding 
priorities concerning illicit drugs put into effect by 
a government or its representatives. Estimation of 
drug-related public expenditure can be seen as a 
fundamental step in the process of policy evaluation. 
A subsequent step would be to systematically com-
pare public expenditure and other possible costs to 
the policy’s measured outputs or results. Depending 
on how policy results are defined and measured, a 
cost-benefit or cost-effectiveness analysis could be 
conducted (see glossary). In this case, resource inputs 
(the costs of labour, capital and/or equipment) are 
linked to intermediate outcomes (e.g. number of 
drug dealers arrested), final outputs (e.g. lives saved, 
life years gained, number of drug users, reduction in 
drug-related harm, percentage reduction in crimes 
committed), or policy goals. Regardless of the selected 
output measures, however, public expenditure will be 
a central cost factor, since governments constitute 
the main provider of drug supply reduction services 
in Europe. 
A thorough economic evaluation can provide poli-
cymakers with the information required to make 
well-informed decisions. Although the data and a 
quantification of all the outcomes and cost elements 
required for conducting the most comprehensive 
analyses are currently not available, a somewhat less 
extensive analysis and an improved understanding 
of the individual elements involved are still possible, 
useful and desirable. This report takes the first step 
towards a systematic analysis by examining a number 
of representative attempts to estimate public expendi-
ture on drug control policies. It proposes a common set 
of definitions to be used for public expenditure assess-
ment and evaluation. In addition, it aims to establish a 
common basis for understanding this complex subject 
and to facilitate comparability in three main areas: 
time, policy and countries concerned. Although the 
report mainly focuses on drug control expenditures, in 
order to contextualise them, it also details total drug-
related expenditure as a proportion of gross domestic 
product. It further shows how spending is balanced 
between demand and supply reduction initiatives 
in a number of European countries. To facilitate and 
promote future empirical expenditure studies, the 
relevant data sources and methodologies applied in 
making empirical estimates are listed and discussed. 
Examples of sectorial models of public spending and 
examples of national supply reduction expenditure 
studies are also provided. Finally, some conclusions 
and recommendations are offered. 
Appendix 1 presents international sources that have 
published data in this field and summarizes their 
data. While aggregate data for broad classes of public 
expenditure have been published for two decades, 
data trends for drug-related expenditure on control 
policies are not available. Specific data reflecting the 
activity of national drug control policies, such as the 
number of criminal offences or the evolution of the 
prison population, are available. However, data such 
as these require adequate modelling before being 
ready to be used in estimates of public expenditure 
on control policies.
Page 12 ► Costs and unintended consequences of drug control policies
Defining concepts
Public expenditure
The term «public expenditure» refers to the value of 
goods and services purchased by general govern-
ments (at central, regional and local levels) in order 
to perform their functions. For example, it refers to 
resources spent on healthcare, justice, public order 
and safety, education, social protection and so on 
(12). Public expenditure is quantified by cost exercises 
conducted by governments (10). The role of private 
expenditure in drug policy varies across countries, 
timescales and policy areas. In many countries, drug 
treatment is partly financed by the private sector 
(insurance companies, drug users or their employ-
ers, relatives, etc.). In other drug policy areas, such as 
supply reduction, private funding usually constitutes 
a negligible share of total spending (13). 
Drug-related public expenditure
Drug-related public expenditure is the sum spent by 
governments on goods and services with the aim 
of tackling the illegal drug phenomenon. Although 
drug policy expenditure estimates are deemed use-
ful, most countries do not produce separate drug-
related budgets as part of their ordinary budgeting 
exercise. Relevant analyses and estimations can be 
complicated since several inter-ministerial and cross-
governmental sectors are involved in drug control 
programmes, including justice, policing and border 
control, prisons, social protection, education and 
health. Disentangling drug policy expenditure across 
government departments and inter-sectorial policies 
remains a significant challenge. Changes in legislation 
and the structure of public administration can further 
hamper comparability over time.
An additional challenge lies in the fact that drug-
related programmes and activities can be found at 
many different levels of public administration. For 
instance, funding for imprisoning drug-law offenders 
is usually provided by the central government, while 
prevention of street dealing or social reintegration 
programmes for former drug dealers are frequently 
financed by local authorities. This makes it necessary to 
compile data at different administrative levels, which 
can be a demanding task. 
In addition, often only a small fraction of drug-related 
public expenditure can be traced directly back to 
government documents or single budget lines and 
are labelled as such. The required data for drug-related 
public expenditure are instead embedded in budgets 
for larger sectors or programmes (unlabelled expen-
diture), which means that modelling and calculations 
are required to produce clean data. For instance, it is 
common that prisons do not have a separate budget 
for drug-law offenders, because they usually have 
one single budget for their entire activity. Therefore, 
the values of this embedded expenditure can only 
be estimated through modelling approaches (14). 
This requires skills, modelling tools and techniques. 
Despite various factors which may challenge the 
robustness of estimation results (limited data avail-
ability, layering of assumptions, changes in defini-
tions or regulations over time, etc.), the application of 
existing models can provide useful insights, as various 
countries’ experiences show (see the examples below). 
Public expenditure on supply reduction 
initiatives
In this report, public expenditure on drug supply 
reduction comprises the funds spent by the general 
government with the broad purpose of reducing the 
availability of illegal drugs with the support of the 
police, law courts and prison services geared towards 
countering the illegal drug phenomenon, as defined 
by Eurostat (12). In general, police services comprise 
enforcing national laws and regulations, including 
factors such as crime prevention and investigation, 
the regular and auxiliary policing of ports and bor-
ders, coast guards and customs, as well as road traffic 
regulations and supervision. The services provided 
by law courts comprise the operation or support of 
civil and criminal law courts and judicial systems, the 
prosecution service, fine enforcement and probation 
systems. Prison services comprise the activities of 
prison administrations and the operation or sup-
port of prisons and other places for the detention 
or rehabilitation of criminals, such as prison farms, 
workhouses, reformatories, borstals, asylums for the 
criminally insane, etc. (12). 
In the case of public expenditure on drug supply 
reduction initiatives, the vast majority of resources 
are spent on enforcement targeting producers and 
dealers, but may also include legal action targeting 
users for drug possession when required by national 
judicial systems.
Empirical estimates of demand 
and supply policy expenditure
Over the last decade at least 16 European countries 
have provided comprehensive estimates of drug-
related public expenditure (15). Country estimates 
suggest that drug-related expenditure ranged from 
0.01% to 0.5% of gross domestic product (GDP). Since 
the studies may not have applied the same expendi-
ture classifications or the same estimation methods, 
caution is required when making cross-country com-
parisons (15). 
Interestingly, however, the information available sug-
gests that supply reduction activities accounted for 
the largest share of drug-related public expenditure 
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in most countries. Of the 16 countries producing com-
plete estimates in the last decade, only four countries 
spent less than 50% of their total drug budget on 
supply reduction, while five countries spent 70% or 
more. The other countries spent between 50% and 70% 
of their drug-related expenditure on supply reduction. 
Figure 1 Breakdown of drug-related expenditure between demand and supply reduction. 
Source: EMCDDA, 2014b (15)
Analysis has also shown that funds allocated to drug-
related initiatives account for only a small proportion 
of the overall public expenditure in the “public order 
and safety” sector. For instance, in 2008 (the only 
year this exercise was systematically conducted in 
European Union countries), supply reduction expen-
diture represented between 2% and 12% of total 
public expenditure in this sector, while the propor-
tion of drug-related expenditure on these items 
accounted for less than 1% of total public spending 
in the “health and social protection” sector during that 
same period. Since most public spending on demand 
reduction initiatives is classified under “health and 
social protection,” these figures may suggest that 
European countries give higher political priority to 
supply reduction initiatives as part of public order and 
safety activities than to demand reduction initiatives 
as part of overall public health activities (10). Annually, 
EMCDDA reports the most recent estimates available 
for national drug-related public expenditure in the 
European Union countries, Norway, and Turkey as a 
percentage of gross domestic product (GDP). When 
available, EMCDDA also reports the proportion of 
funds spent on supply reduction initiatives (http://
www.emcdda.europa.eu/countries). 
Steps in cost estimation and analysis
Clarifying definitions, improving estimation meth-
ods, agreeing on best practices and finding reliable, 
standardised data will enhance the utility of pub-
lic expenditure estimates, as analysis over time and 
across policy areas and countries can be improved 
(16). Better quality data and further methodological 
developments are needed. To this end, we recom-
mend some general methodological steps in cost 
estimation and analysis. 
Defining the scope and objects
Globally speaking, a first step for a viable cost estimate 
is defining the scope and type of public expenditure 
considered. In addition, it is necessary to clearly indi-
cate which geographic area and which function of 
public service provision the estimates cover. 
Making an inventory of service providers
Secondly, it is necessary to identify the public entity or 
institutions responsible for the provision of drug-re-
lated services – in the case of this report, supply reduc-
tion measures and interventions. The government 
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authorities and public institutions and services respon-
sible for the implementation of drug policy initiatives 
at different competency levels must be inventoried. 
Mapping financing entities
The third step is to identify the different public author-
ities and institutions that fund aspects of drug policy 
and finance service providers. Regardless of govern-
mental structure, expenditure by all relevant national, 
regional or local government institutions, directly or 
indirectly associated with drug policy, should always 
be included in a cost estimate.
Matching stakeholders responsible for providing drug 
policy services with their financing entities can be 
challenging, as the entities in charge of providing 
public services are not always obvious and easy to 
identify. For instance, when drug treatment services 
are provided within prisons, the entity in charge has 
public order and safety as its first function but health 
as its objective in this situation. Therefore, analysts 
must consider whether to include the costs of these 
activities as supply reduction or demand reduction 
initiatives. Eurostat, along with most international 
organisations concerned with policy evaluation, 
includes the provision of services as the main method 
to identify which sector funds are used for, even where 
the provider is less obvious. In this case, public expen-
diture on drug treatment provided in prisons should 
be excluded from expenditure estimates for supply 
reduction services and accounted for as drug-related 
health expenditure. Sometimes, provision will be the 
responsibility of private entities while financing is a 
government responsibility. 
It should be noted, however, that the same service may 
have multiple policy purposes and duplication should 
be avoided. For instance, in the case of social reinte-
gration programmes in affected neighbourhoods, 
financing may serve both the purpose of preventing 
drug crime (supply reduction expenditure) and the 
purpose of preventing drug use (health spending in 
demand reduction expenditure). For public account-
ing purposes these funds should not be counted twice. 
Therefore, researchers will have to include this expen-
diture only once, choosing to record it under either 
preventive health or crime prevention. Sometimes, 
deciding in which sector to include the expenditure is 
difficult and the best way to deal with such situations 
is to ensure that researchers document the different 
choices and assumptions they make.
Data collection
The fourth step is to determine a strategy for collect-
ing the required data on public expenditure. In order 
to obtain relevant information, analysts will have to 
examine policy documents and accounting data. It is 
also recommended that interviews be conducted with 
the major stakeholders in the field as a way to obtain 
better information about where financial data might 
be available, and to search for international data sets. 
Classifying and identifying data 
on drug-related spending
It is essential to classify public expenditure according 
to the purpose for which the expenditure is intended 
(12;17). The next step to consider is how to group 
drug-related spending according to these sub-pur-
poses. Two classification systems are commonly used: 
► Taking into account the fact that drug-related 
expenditure on supply reduction initiatives 
comprises funds spent with the aim of address-
ing the illegal drug phenomenon through the 
police, law courts and prison service, the clas-
sification frequently used in international com-
parisons is the Classification of the Functions 
of Government (COFOG).1 Under COFOG, most 
drug control policy expenditure is included in 
the “public order and safety” class of expendi-
ture. The most directly relevant subclasses are 
“police services”, “law courts”, “prisons” and “R&D 
public order and safety” (12). 
► Reuter (20) relates public expenditure to the 
supply and demand sides of the market, and 
subdivide public costs according to four govern-
ment programmes; prevention, enforcement, 
treatment and harm reduction programmes. 
He counts public spending on supply reduc-
tion under “enforcement programmes” and 
considers that these are “programmes aimed 
at traffickers and producers to shift up the supply 
curve for drugs; other things being equal, they 
should raise the price of drugs and lower quantity. 
Programmes aimed at users and retailers raise 
the transaction costs of buying drugs”. In other 
words, enforcement programmes will make 
drug producing, trafficking or dealing more 
expensive, because they either bring about 
an increase in the unitary costs of production 
or introduce greater risk into the business (21).
These two classification systems are substantially 
different. COFOG was co-designed by the statisti-
cal office of the European Union and the European 
Commission, with well-defined concepts and data 
collection methodologies. Annual mandatory data 
collection has been implemented in every European 
Union member state since early 2000. The system 
covers all functions provided and financed by gov-
ernments. Though drug-related activities are among 
the overall tasks provided and financed by the public 
sector, there are no specific methods specified or data 
collected on drug-related expenditure. Drug-related 
1. National estimates sometimes use alternative definitions. 
See Lievens et al., 2016 (18) or Kopp, 2006 (19) for further 
details.
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expenditure is embedded in broader items, such as 
public expenditure on public order and safety, security, 
health, education or social protection. Conversely, 
the Reuter’s classification was designed to organize 
public expenditure spent with the main aim of tack-
ling the drug phenomenon. Despite the fact that no 
systematic data collection is based on this system, 
it is frequently applied in empirical estimates (see 
examples in section 2.6 below). 
The research community has not formally adopted 
either of these classification systems. As Eurostat 
publishes data annually in accordance with the COFOG 
classification, their system has some advantages, 
although researchers have to choose criteria and 
design models to disentangle drug-related spending 
within the overall expenditure classes.
As mentioned, supply reduction initiatives are often 
embedded in policy projects that have broader objec-
tives and budgets. Therefore, it is important to first 
look beyond expenditure that is exclusively used for 
drug policy and to also include spending intended 
for broader policy domains that indirectly, but sig-
nificantly, contribute to or impact drug policy. For 
instance, investing in effective policing in certain 
neighbourhoods, in order to prevent all types of 
crime, may also contribute to preventing drug dealing. 
Consequently, it is relevant to take into account overall 
budgets for initiatives which may have direct synergies 
with drug policy objectives. Secondly, modelling tech-
niques are required in order to extract drug-related 
expenditures from overall expenditures. For example, 
specific estimates and well-defined methodologies are 
needed to disentangle expenditure on drug-related 
crime from overall public spending on law courts 
(more details on methodologies are given below). 
In the event that not all the required data are available 
in international data sets, national databases should 
be mapped. Each country has different structures for 
drug control services, provision and financing. National 
data mapping can be achieved in different ways, such 
as extracting information from registration systems 
and annual reports or by interviews with key experts 
and/or contacts working in this field (22). Detailed 
mapping of available data can be demanding and 
makes intensive use of resources. However, it is a 
fundamental step for any estimate of public spending 
on drugs control.
Extracting expenditure data: labelled 
and unlabelled expenditure
Some of the funds allocated by governments for 
drug-related expenditure are identified as such in the 
budget (labelled expenditure). However, the majority 
of drug-related expenditure is often not identified 
(unlabelled expenditure) and must be estimated using 
modelling approaches. Total drug-related expenditure 
is the sum of labelled and unlabelled drug-related 
expenditures (23).
Since labelled expenditures are clearly identified in 
budgets, calculation methods are not required. Time 
series data are often available for labelled expenditure. 
The biggest challenge when data on labelled expen-
diture are compiled is to ensure complete mapping 
of all entities in charge of providing these services, as 
they can be spread across different government levels. 
Depending on the national structures, expenditures 
from all relevant national, regional or local government 
institutions that are directly or indirectly associated 
with drug policy should always be included.
For unlabelled expenditure, a modelling procedure 
is necessary and the modelling is based on either a 
top-down or a bottom-up approach. Frequently, these 
estimates require the use of activity data to develop 
estimates, such as the number of offences, offenders, 
criminal cases, or prisoners.
Modelling unlabelled expenditure
The top-down modelling approach is mainly used 
when the data available are embedded in programmes 
with broader goals and the fraction attributable to 
drugs can be identified as a proportion of the overall 
budget. In order to identify this proportion, models 
identify objective criteria and calculate attributable 
fractions. 
Unlabelled drug-related expenditure = Overall expenditure × Attributable fraction
There is no general methodology to determine attrib-
utable fractions, also known as repartition keys. In 
practice, the appropriate repartition key is deter-
mined by the object of the estimate, data availability 
and the modelling approaches available. Repartition 
keys are determined in different ways on the basis of 
information from activity data. These activity data are 
extracted from registration systems, annual reports 
and/or contacts working in this field (22). When deter-
mining attributable fractions, the data used should 
preferably be publicly available or, even better, stored 
within international databases. This can guarantee the 
possibility of producing comparable estimates in the 
years that follow and in other countries.
Appendix 3 summarizes information on the data 
available in the most relevant international data-
bases that can be used to estimate unlabelled public 
expenditure on supply reduction. It describes the 
activity data reported, the reporting countries and 
time periods. This appendix reports the data available 
concerning annual statistics on national public expen-
diture on police, law courts and prisons reported by 
Eurostat. These data include not only expenditure on 
drug-related initiatives, but the total spent on all crime. 
Therefore, to extract drug-related expenditure and 
build attributable fractions, activity data is required. 
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For example, data on the number of drug-law offend-
ers in prison compared with total prison population 
will allow researchers to estimate drug-related prison 
expenditures as a proportion of total prison spend-
ing. Additionally, the number of drug-related cases 
handled by police, prosecutors or drug-law courts 
compared to the total number of cases handled by 
these institutions may also allow researchers to esti-
mate their drug-related costs.
To design attributable fractions, models may use data 
on crime, police, law court or prison activity. Appendix 
3 presents information and data by groups of variables. 
These groups encompass total public expenditure, 
drug-related public expenditure, supply reduction 
public expenditure; drug law offences; crime reported 
by the police, drug-related crime, conviction statistics 
and prison population. Within these groups, relevant 
variables are listed. For each variable, available data 
are listed by source, country and time period. Finally, 
this appendix reports the number of observations 
available for each variable. Relevant sources include 
data from the Council of Europe, EMCDDA, EUROSTAT, 
Institut de Criminologie et Droit Penal de l’Université 
de Lausanne and the UNODC. 
Despite the fact that some of the data are only avail-
able for a short period of time and that data are still 
missing in many countries/years, gathering informa-
tion that is available will allow researchers to develop 
better methods and more accurate estimates in the 
future. 
When international sources are not available, publicly 
available national statistics and data from competent 
public bodies should be used.
Advantages of the top-down approach
► Availability of data: Aggregated budgetary data 
are often readily available which means that 
top-down approaches can be easily applied.
► Low cost: the availability of aggregate data 
means that the time and costs required to esti-
mate a top-down unit cost can be reduced.
► Versatility: the methodology enables an ana-
lyst to forecast how costs may change as a 
result of a reduction/increase in service usage 
(for example, when there are less/more drug-
related crimes committed in a certain year than 
expected) and how these costs change over 
time.
There are, however, some limitations associated with 
a top-down approach. A top-down approach may 
not clearly identify different factors that drive costs 
and therefore often masks the underlying factors 
that determine why unit costs vary within a single, 
yet heterogeneous, service group. The criteria laid 
down for estimating attributable fractions do not 
always take into account all of the characteristics 
that may impact the total costs, which means that 
cost functions are often simplified. These estimates 
therefore may not often be very precise. Nevertheless, 
they are frequently used and provide valuable proxy 
indicators for average costs. 
An alternative method of estimating drug-related 
expenditure is to base estimates on the cost of pro-
viding one unit of public service, known as the bot-
tom-up modelling approach. For instance, how much 
does it cost to keep one drug-law offender in prison? 
Considering the different costs borne by the govern-
ment for managing a prison facility, such as the real 
costs of state property, prison staff, electricity, water 
and gas, machinery, etc., it is possible to estimate how 
much each detainee costs per day. This sum can then 
be multiplied by the number of drug-related detain-
ees, taking into account different costs associated with 
each type of detainee, based on the different lengths 
of prison sentences, different security levels, etc. To 
obtain the total expenditure on drug control policy, 
all cost elements should be identified and totalled. 
The bottom-up approach is particularly appealing 
when relevant unit costs are readily available. If, on 
the other hand, every type and element of the drug 
policy has to be separately estimated, the approach 
can be demanding and challenging. 
Advantages of using a bottom-up approach
► Transparency: detailed cost data allow potential 
errors to be investigated and their impact tested 
– this facilitates a quality assurance process.
► Simplicity: the calculation required to estimate 
unit costs is direct and easy to understand, pro-
viding a simple way to quantify administrative 
and overhead costs associated with a range of 
public services.
► Detail: detailed cost data can highlight varia-
tions, enable analysts to explore factors under-
lying variations and determine whether, for 
example, some service users account for a dis-
proportionate share of the costs.
► Versatility: the methodology enables an analyst 
to forecast how costs may change as a result of 
a reduction in service usage or demand.
The main disadvantage associated with the bottom-up 
approach is that it requires detailed information con-
cerning both the type of costs associated with the 
provision of each service (full knowledge of the pro-
duction function of each public service) and the unit 
cost of each of the production factors. 
A combination of the two approaches may be pre-
ferred. The advantage a dual method is that it makes 
cross-verification possible; the data gathered in a 
top-down approach can be double-checked and 
supplemented with the data retrieved from project 
actors in the field.
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Reporting the value of estimates
The basic format used to report the value of estimates 
is monetary value in nominal terms. However, to 
permit comparability over time, estimates should be 
adjusted for inflation if reported in monetary units. 
Some authors, however, report the value of estimates 
as a percentage of GDP. This way of presenting results 
considers the economic dimension of a country. It is 
likely that drug-related spending is higher in a country 
with 85 million inhabitants than in a country with 
10 million inhabitants. The same holds for a higher 
income country (10). For these reasons, reporting the 
value of estimates as a percentage of GDP is a valid 
choice, since it takes account of both inflation and 
the size and level of a country’s income.
Another frequently used approach is reporting the 
value of spending per number of problem drug users. 
In this case, authors take into account the context of 
the drug problem. Reporting all complementary mea-
surements of drug-related public spending facilitates 
the validation of the data through cross-verification 
and increases the economic significance and utility 
of the estimates.
Examples of sectorial models
In addition to collecting labelled public expenditure 
data, several models have been applied to identify unla-
belled expenditure on drug control in national contexts. 
Different authors have applied different definitions, 
data sets and models to estimate items of drug-related 
expenditure. This section presents examples of models 
used to estimate unlabelled drug-related spending on 
various types of supply control initiatives. 
Police
Public spending on drug-related police services is 
probably best identified using a top-down approach.2
In order to disentangle this expenditure from total 
public expenditure on public order and safety, as 
published by Eurostat, attributable fractions have 
been calculated with the help of activity data, such as 
drug-related offences in proportion to the total num-
ber of offences. The following are concrete examples 
of variables available in national and international data 
sets, which have all been used separately to estimate 
attributable fractions:
(1) The number of drug-related crimes per 100 000 
population.
2. Although it is also possible to use a bottom-up approach, 
since police activity is normally financed by the central gov-
ernment budget, a pragmatic approach frequently used is to 
prepare estimates based on these aggregated budgets. In this 
case, estimates for public spending are relatively complete, 
considering all relevant costs. Additionally, this method 
facilitates the international comparability of results, since 
comparable data are available for most European countries.
(2) The number of drug-related cases reported 
by the police out of the total number of police 
cases.
(3) The time the police forces spend on countering 
the drug phenomenon in proportion to their 
total working time.
To estimate the share of costs attributable to spending 
on police action against illicit drugs, the ratio is multi-
plied by the total expenditure of the law enforcement 
agencies and reduced by any available data on labelled 
expenditure for drug control. 
A concrete example is provided by the estimates for 
Italy. Genetti (24) estimated drug-related public expen-
diture for police forces based on the amount of time 
that staff spent on drug control in 2011: possession 
of illicit drugs for personal use; production, trafficking 
and dealing in illicit drugs; and driving under the 
influence of drugs and alcohol. The proportion that 
this time represented of the total working time for 
the police forces was then used as an «attributable 
fraction» for disentangling the amount of money that 
was spent on drug-related police activities from total 
spending on police activity. Within the funds allocated 
for drug control, 14% was spent on drug-police activity, 
while law courts and prisons spent the remaining 21% 
and 65% respectively.
Moolenaar (25) developed a model and provided an 
example of how to estimate public spending on supply 
reduction initiatives in the Netherlands. The author 
applied a top-down model based on the average cost 
of police time spent on this work. Moolenaar calcu-
lated the average duration of each type of criminal 
investigation first by type of criminal activity (assum-
ing that different criminal activities have different 
investigation costs based on an assessment of the 
severity of the crime) and second by the number of 
cases registered for each criminal activity.
Customs
With regard to customs services, the share of customs 
officers who deal with drug control activities and/or 
the proportion of their working time compared to 
the total number of custom officers and/or the total 
working time has been used as an attributable frac-
tion. As input data, the number of customs officers 
who are involved in drug control activities forms 
the basis for calculation. These estimates are then 
applied to total expenses of the customs adminis-
tration (minus any labelled expenditure specifically 
targeted towards this activity). It should, however, be 
noted that most customs officers do not exclusively 
devote their working time to drug control activities, 
so, ideally, the percentage or the average of working 
time devoted to drug control should be estimated.
Kopp and Fenoglio (26) estimated the drug-re-
lated expenditure of customs services based on the 
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proportion of customs officers allocated to addressing 
illicit drug trafficking within the total number of cus-
toms officers. This proportion constituted the attrib-
utable fraction applied to the total customs budget. 
The authors concluded that, in 2000, drug-related 
spending on customs services represented approxi-
mately 10% of total drug-related spending in France. 
As these authors pointed out, omitting costs such as 
those of detection equipment or detection dogs may 
be considered a relevant limitation, since these costs 
may have a strong impact on relatively small budgets, 
such as customs services.
Lievens et al. (18) estimated drug-related expendi-
ture by customs based on the proportion that drug-
law violations represented of the total number of 
violations registered by ordinary customs services, 
investigation services and motorised brigades. They 
used a top-down approach based on the number of 
drug-law offences as a proportion of the total number 
of offences. In 2012, customs spending represented 
3.6% of the total drug-related public spending on 
supply reduction in Belgium.
Court systems
Spending on drug-related court services has been 
extracted from total national expenditure on law 
courts based on the following activity data: 
(1) The proportion of drug-related offences with 
regard to the total number of offences.
(2) The proportion of drug-related convictions with 
regard to the total number of convictions;
(3) The proportion of people imprisoned for 
drug-related offences with regard to the total 
number of prisoners.
Kopp and Fenoglio (26) estimated the expenditure 
that drug-related crime represented in the French 
judicial system. They adopted a bottom-up approach, 
taking estimates of the time spent by various types of 
French judges and other types of administrative staff 
on drug-law cases and then multiplying these esti-
mates by their average salaries. Based on this method, 
the authors concluded that law courts represented 
about 24.4% of total drug-related public expenditure 
in France in 2000.
In Croatia, drug-related spending on the courts covered 
drug-related cases prosecuted by both the State and 
the courts (27). A top-down approach was used based 
on estimates of the number of drug-related crimes as 
a proportion of the total number of crimes registered 
by the police. The researchers recognised that these 
estimates were crude, but they could not obtain a better 
proxy for this particular component of the estimates. 
In Sweden, expenditure on drug-related prosecutions 
and court cases (district court, court of appeal and 
supreme court) was estimated based on a bottom-up 
approach, which combined the number of cases and 
the average cost per case (28). The data were obtained 
from a judicial system official. It should be noted that 
the average case cost was not recorded by type of 
crime; instead the average for all types of crime was 
used as an indicator for drug crimes. Moreover, for the 
court of appeal and supreme court, only the total num-
ber of criminal cases was available and the proportion 
of drug cases was estimated based on case numbers 
in the district courts (9%). Regarding the range of the 
estimates, it should be noted that the author included, 
as an upper limit, a specific percentage (30%) of the 
costs of addressing other crimes, as they may have 
been committed under the influence of drugs. 
Prisons
Unlabelled costs of drug-law offenders in the prison 
system can be estimated using the number of con-
victed prisoners for drug-related offences expressed 
as a proportion of the number of overall convictions. 
For example, to estimate expenditure related to drug-
law offences in prisons, two elements must be taken 
into account: overall prison expenditure for a given 
fiscal year and the attributable fraction of prisoners 
convicted of drug-law offences. 
EMCDDA (14) provides an example of how public 
expenditure on drug-law offenders in prisons can be 
estimated. Based on data for public expenditure on 
prisons provided by Eurostat and data on the number 
of offenders provided by the Council of Europe, the 
proportion of prisoners sentenced for a drug-law 
offence as their main offence was compared with 
total public expenditure on prisons. A range of esti-
mates was calculated, with low estimates taking into 
consideration only prisoners sentenced for a drug-law 
offence and high estimates also including pre-trial 
prisoners. Between 2000 and 2010, this expenditure 
was estimated to range, on average, between 0.03% to 
0.05% of GDP in 22 European countries. On applying 
these percentages to the entire EU for the year 2010, 
the estimated expenditure was within the range of 
3.7 billion euros to 5.9 billion euros.
Examples of national studies
Several models and data sources have been applied 
in different national contexts to identify labelled and 
unlabelled expenditure allocated to drug control 
initiatives. Due to national specificities, neither their 
external validity nor the comparability of the methods 
used have been tested. The extent and specificity of 
labelled drug-related expenditure vary substantially 
across countries, as do the data and methods applied 
for estimating unlabelled expenditure. Due to this, the 
national estimates presented below are not directly 
comparable; however, they do provide examples of 
useful models and estimates and illustrate some of 
the approaches applied. 
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Croatia
Budak et al. (27) aimed to identify the central gov-
ernment’s total drug-related public expenditure and 
to develop a method of estimating and allocating 
unlabelled expenditure by type of drug policy pro-
gramme (prevention, treatment, social reintegration, 
harm reduction and law enforcement). For labelled 
expenditure, governmental institutions were asked 
to classify budget expenditure by public function 
and by type of programme. Unlabelled expenditures 
were identified indirectly with a system of reparti-
tion keys, which were applied to the total state unit 
budget (minus labelled costs). The repartition keys 
were estimated using supply reduction activity data. 
Unlabelled public expenditures were estimated on 
the assumption that they make up the part of public 
expenditure remaining after labelled public expendi-
tures for countering drug abuse have been deducted 
from the total expenditure of a public body. 
For the period of 2009-2012, the study suggests that 
public expenditure on law enforcement constituted 
about 73% of total drug-related public expenditure by 
central government, whereas prevention, treatment, 
social reintegration and harm reduction represented 
12%, 13%, 0.3% and 2%, respectively. When comparing 
unlabelled expenditure for different programmes in 
a single year (2011), unlabelled expenditure on law 
enforcement represented 82% of total unlabelled 
drug-related expenditure. On the other hand, law 
enforcement accounted for 4% of total labelled expen-
diture. Overall, the estimates indicate that drug-related 
expenditure accounted for 0.2% of GDP.
Belgium
The study Drugs in Figures III measured how much the 
Belgian Government spent on drug policy in 2008 
(29). It expanded upon two earlier studies (30;31) by 
carrying out a new and more refined estimation of 
public expenditure to counter illegal drugs. The study 
combined a top-down and a bottom-up approach 
for estimating public expenditure. The vast majority 
(98.45%) of the expenditures were identified as a 
result of the top-down approach. Public expenditures 
identified through the bottom-up approach (1.55%) 
were related to organisations that depended on the 
government for most of their funding.
Total drug-related expenditure was broken down 
by programme: law enforcement, treatment, pre-
vention, harm reduction and other. For 2008, public 
expenditure on law enforcement constituted 45% 
of the total expenditure. This was slightly less than 
the total spent on treatment (49%) and substan-
tially more than that spent on prevention (4%), harm 
reduction (0.8%) and other (1.2%). When estimated 
in the same way for 2004, public expenditure on law 
enforcement showed a substantial increase between 
2004 and 2008, both nominally (from 186 038 337 
euros to 243 000 490 euros) and in relation to other 
programmes (it increased by 6 percentage points).
Italy
For the purpose of estimating drug-related public 
expenditure in Italy (32), a model was developed to 
analyse the flow of cost information from various 
sources. The model consisted of four components: pri-
vate or indirect costs (individual costs and costs due to 
loss of productive capacity) and public expenditure or 
direct costs (law enforcement costs, social and health 
costs). To determine the costs of law enforcement, 
the following sources of information were used: data 
concerning traffic control and traffic accidents, police 
data on people caught with drugs for personal use, 
data on the number of convictions for drug trafficking, 
and data on crimes related to drug trafficking.
For 2011, the cost of drug-related law enforcement 
was estimated at 1 600 435 296.60 euros, or roughly 
40 euros per inhabitant aged 15-64 years. The largest 
cost component was prisons and alternative measures 
(65%), whereas trials and legal expenses, law enforce-
ment activities and administration represented 21.3%, 
13% and 0.7%, respectively.
France
In a French study, the method relied on analysing 
activity records wherever available in relevant agen-
cies (33). The total expenditure for drug-related activ-
ities in these agencies was then aggregated. The 
top-down approach applied in this case provided an 
indication of the proportion of expenditure for drug 
control related activities compared to the overall 
expenditure of all relevant institutions and agencies. 
To obtain an estimate, a fraction was applied to the 
total staff and routine operating costs of the agency 
concerned. In the year 2010, for example, 10% of police 
activities were attributable to drug control activities, 
which involved 60 police units. In this example, police 
expenditures attributable to drug-related activities 
were calculated by multiplying the total expenditure 
of the police services by this fraction of 10%. 
A bottom-up approach was also adopted, based on 
the working time of staff performing support func-
tions in connection with drug-related activities or the 
equipment used, as recorded by relevant agencies. 
For example, the time spent giving prevention talks 
in schools and the time spent by the police forces on 
alcohol tests were included in the calculations.
According to Kopp (33), the French government 
spent 913 million euros in 2010 on ‘prevention and 
repression,’ which represented close to 40% of total 
drug-related public expenditure (total drug-related 
expenditure was estimated at 1% of GDP).
Page 20 ► Costs and unintended consequences of drug control policies
Luxembourg
Since 1999, the social costs of drugs have been esti-
mated annually in Luxembourg. These estimates take 
into account the total costs of the consequences of 
drug use and trafficking to public and private agents. 
Public spending is analysed in five sectors: prevention, 
treatment, harm reduction, law enforcement and 
research. In the law enforcement field, as in other fields, 
the analysts face the twofold challenge of accounting 
for drug-related spending, as financed by different 
general government levels, and of developing models 
to extract unlabelled drug-related expenditure from 
broader budgets (34).
Law enforcement was estimated to account for 39% 
of total drug-related public expenditure in 1999; 
prevention, treatment and harm reduction expendi-
ture amounted to 59%, whereas research and other 
accounted for 2%. Overall, drug-related public expen-
diture represented 0.013% of GDP.
Russia
For Russia, public expenditures on law enforcement 
agencies and on the judicial system were estimated as 
part of a social study (35). The comprehensive model 
encompassed private and indirect costs (the cost for 
the individual and the costs due to loss of produc-
tion capacity) and public spending, including direct 
spending on supply reduction services. These were 
disaggregated into spending on law enforcement 
and on criminal justice, which included factors such 
as law enforcement agencies and the federal drug 
control service. 
Public expenditure on supply reduction services was 
estimated using a top-down approach and various 
sources of information: police data on persons caught 
with drugs for personal use, data on the number of 
sentences for drug trafficking, and data on crimes 
related to drug trafficking. As there was no published 
information on the fraction attributable to drug-re-
lated crime in Russia, the fraction estimated in a study 
by the US Office of National Drug Control (22%) was 
employed in order to estimate law enforcement and 
judicial system expenditures. 
Portugal
There are few examples of attempts to estimate 
the impact of changes in the legal system on drug-
related public expenditure and drug-related bud-
gets. Gonçalves et al. (36) are an exception, as they 
conducted a comprehensive social cost analysis of 
the situation before and after decriminalisation in 
Portugal. The authors found a significant reduction in 
the non-health related costs of drug policy between 
2000 and 2004, particularly in the legal system (direct 
costs). Although these observations highlight signifi-
cant changes, prudence is still necessary in concluding 
a causal relationship between the reduction in drug 
policy costs and the new Portuguese National Strategy 
for the Fight against Drugs (NSFAD).
Other national studies
There are other examples of public expenditure stud-
ies in addition to those listed above. For example, 
Mostardt et al. (37) estimated public expenditure in 
2006 for Germany using data from Eurostat and the 
COFOG system, concluding that supply reduction 
represented close to 65% of the total drug-related 
public spending; Rigter (38) estimated that 75% of 
public expenditure was spent on law enforcement 
in the Netherlands; Ramstedt (28) presented public 
expenditure estimates for Sweden, concluding that 
public spending on supply reduction represented 
between 70 to 76% of the total; and Lievens et al. 
(18) published a social cost study, including estimates 
of public expenditure on legal and illegal drugs in 
Belgium. There are also US (39) and Australian (40) 
estimates. Despite substantial differences, the studies 
may all be viewed as necessary foundations in national 
drug policy evaluations. 
International estimates and 
databases used to model drug-
related public expenditure
The only available international compilation of 
updated estimates of drug-related public expenditure 
on supply reduction is published by the EMCDDA for 
EU member states (41), which reports the available 
national estimates of total drug-related spending sepa-
rated into supply and demand reduction initiatives. 
However, the scope for cross-country comparisons is 
limited because country estimates often do not use 
comparable definitions, data sets or methodologies.
Another database of particular relevance is Eurostat 
because it is based on a consistent categorisation sys-
tem and on internationally agreed definitions, which 
are required features for international comparison. The 
Classification of the Functions of Government (COFOG) 
is a detailed classification system for the functions or 
socioeconomic objectives that general government 
units aim to achieve through a range of outlays (for 
more details, see Appendix 2). Eurostat has published 
annual data according to the COFOG classification for 
European countries since the early 1990s. This data 
source has proved to be relevant and amenable to a 
wide variety of analytic applications. However, the 
data set does not comprise data concerning specific 
spending on drug-related public initiatives. In order to 
extract drug-related expenditure from broad classes of 
public spending, modelling approaches are adopted 
according to the sector of intervention. 
Appendix 1 provides a list of relevant data sources. In 
addition to the two data sources already mentioned, 
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there is information on international reporting con-
cerning supply reduction factors such as drug related 
crime (EMCDDA and the European Institute for Crime 
Prevention and Control), prison activity and costs (the 
Council of Europe), and crime and criminal justice 
systems (Eurostat and the European Institute for Crime 
Prevention and Control). Appendix 3 and the web site 
http://www.emcdda.europa.eu/topics/drug-related-
public-expenditure make an extensive description of 
data published by international institutions. 
Conclusions
► Each European country allocates significant 
public resources to the drug policy field. Public 
expenditure studies can reveal how much public 
authorities are spending on drug policy and for 
what purposes such expenditure is incurred. 
► Public expenditure estimates can be used as a 
tool for assessing whether policy intentions are 
actually reflected in action, and they constitute 
a necessary tool for implementing thorough 
policy evaluations. Public expenditure studies 
should mirror all relevant activities and policy 
approaches and may be particularly appropriate 
in times of austerity.
► Estimates exist for 16 EU countries out of the 
30 potential reporting countries (42). Estimates 
suggest that drug-related expenditure ranges 
from 0.01% to 0.5% of GDP. 12 out of the 16 
reporting countries allocate the largest share of 
drug-related public expenditure supply reduc-
tion activities. 
► Data availability is one of the main limitations 
in this field. The use of international databases 
is recommended, whenever possible, because 
these data sets employ broadly accepted con-
cepts and definitions and provide better com-
parable data. Sometimes, however, national 
data sets may contain more detailed or reliable 
information. 
► The total budget for supply reduction services 
is the sum of labelled and unlabelled expendi-
tures. Labelled expenditures are clearly iden-
tified in public budgets, whereas a modelling 
procedure is required for estimating unlabelled 
ones. The modelling is based on either a top-
down or a bottom-up approach. Using both 
approaches as complementary is advantageous 
but expensive. A list of advantages and limita-
tions for both methods is provided, in addition 
to empirical expenditure studies for supply 
reduction activities in some European countries. 
► While recognising the limitations presented by 
the data sets currently available, this report pro-
vides examples of current practice and, in doing 
so, suggests areas of future focus for desired 
methodological development. It is hoped that 
the estimation of drug-related public expendi-
ture on supply reduction initiatives and policy 
evaluation will move forward in Europe. For 
continued improvements, however, it is essential 
that a network of experts is developed and main-
tained. Partnerships should be extended and 
maintained with the goal of developing good 
practices, standards and guidelines in this field.
Recommendations
1. Improving estimation methods with further meth-
odological developments, agreeing on best prac-
tices, and finding reliable standardised data will 
enhance the utility of public expenditure estimates, 
as it will permit analysis over time and across policy 
areas and countries. 
2. Improving data quality and developing relevant 
data sources is needed for conducting more precise 
estimations of spending on drug control measures 
and to measure the impact of drug control policies. 
One option is to develop guidelines for data col-
lection and economic modelling of evaluations.
3. It is essential to classify public expenditure based on 
the purpose for which the expenditure is intended. 
It is therefore useful to use a consistent categorisa-
tion system, such as the international Classification 
of the Functions of Government (COFOG).
4. Cross-country comparisons are important, but 
they are only possible with a common methodol-
ogy of public expenditure estimates. International 
data sets and modelling techniques need to be 
expanded and improved in order to increase the 
capacity to carry evidence based on drug policy 
evaluations in the drug field
5. A methodology using a set of repartition keys 
according to COFOG categories can be a starting 
point in order to estimate unlabelled drug-related 
expenditures. General agreement among all partic-
ipating countries on definitions and methods will 
help improve the comparability of results between 
countries. 
6. Public expenditure studies involve analytical work, 
which requires adequate human and technical 
capacities in all relevant stakeholder fields. This 
work is important for obtaining the data quality 
needed for aggregation and comparison. To achieve 
this, a network of experts could be established and 
a working group of experts developed.
7. Developing methods to estimate public expendi-
ture on supply reduction requires effective work-
ing partnerships between drug policymakers and 
specialists in the police, law courts and prisons. 
Collaboration with public accountancy experts and 
those in charge of economic modelling is required 
to guarantee meaningful estimates. 
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Chapter 3 
Unintended consequences 
of drug control policies
A
lthough drug policies are aimed at reducing 
drug use and its harmful consequences, pol-
icy interventions can have unintended conse-
quences. Some of these consequences are health-
related and can have direct effects on morbidity and 
mortality, or they can indirectly affect factors such 
as availability, accessibility and utilization of health 
care services. Other unintended consequences are 
not related to health, but rather to an array of social 
and economic consequences for the drug offender, 
their families and society as a whole. Unintended 
consequences are of policy value for two reasons: 
first, they should be taken into account when policy 
decisions are made and second, these unintended 
but predictable effects should be ameliorated when 
possible (20). The purpose of this chapter is to identify 
and discuss unintended consequences of drug control 
policies and identify those who bear them. In addition, 
for each identified unintended consequence, we sug-
gest possible interventions that can be implemented 
to reduce their extent and negative effects. 
Drug law enforcement intends to detect and respond 
to violation of existing drug laws and regulations. 
Enforcement includes actions such as surveillance, 
apprehension, imposition of a fine, and imprisonment. 
A violation of drug laws is associated with a probability 
of detection and a risk of punishment for the offender. 
Punishment aims both to penalize the individual 
and deter others from committing a similar crime. A 
sentence of imprisonment, for example, penalizes by 
restricting the offender’s freedom of movement for a 
period of time. It is, however, not meant to generate 
stigmatization, reduce job opportunities or access 
to health care services. Likewise, a fine is meant to 
reduce the offender’s financial resources, not to limit 
his or her educational opportunities, labour market 
outcomes or travel possibilities, which may be the 
case if the fine is accompanied by a criminal record. 
While bearing in mind the intended effects of drug 
control policies, the focus in this chapter is on these 
unintended consequences that often accompany 
intended ones. 
Political views on optimal responses to drug use 
and drug problems vary substantially across juris-
dictions in Europe and elsewhere. These views may 
also change over time, as illustrated by the observed 
recent changes in legal responses to cannabis use. 
This report does not advocate one particular policy 
option or method of handling the drug situation, but 
aims to present possible interventions that can be 
implemented regardless of what drug regulations and 
law enforcement practices are currently in place. Given 
present drug laws, the aim is to suggest interventions 
that can reduce the amount, effects and severity of 
unintended consequences. Some suggestions include 
interventions directed towards reducing health risks 
for drug users and their relatives, some relate to inter-
national cooperation in handling money laundering 
and terrorism, while others comprise suggestions for 
increasing the availability of pain relief medication. 
In total, almost 40 possible interventions are listed 
and discussed. 
One might assume that the bearers of both the 
intended and the unintended consequences are 
the drug market participants only, but this is not 
the case. The unintended consequences affect, to a 
large extent, other people, such as relatives of drug 
offenders, patients in need of pain relief and pallia-
tive care, and society in general. Examples of bearers 
and consequences, given below, include the many 
people who suffer from reduced, or lack of, access to 
pain medication, the children, spouses, and parents 
and friends of drug users that are affected by stig-
matization and by drug users’ increased health risks. 
Other examples of consequences include the threat 
to society induced by the huge financial gains from 
illegal drug production and sale, leading to corruption, 
increased risk of armed conflicts and terror activities, 
economic instability, and more. By focusing on all who 
bear the consequences, in addition to drug market 
participants, this report emphasises that drug laws 
and law enforcement have widespread consequences 
and implications, many of which are unintended, that 
must be taken into account when determining drug 
policy and interventions.  
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In this chapter, the unintended consequences of drug 
control policies are subdivided into two main catego-
ries: health and non-health effects. The discussion of 
both categories is further divided into three sections, 
each with three tables that present i) the mechanism, 
ii) a list of unintended consequences, iii) the bearers 
of these effects (drug market participants and non-
participants) and iv) a list of possible interventions 
to reduce and cope with these effects. The tables are 
inspired by the taxonomy of drug related harms found 
in MacCoun and Reuter (43) but deviate from it by 
only focusing on unintended consequences of control 
policies and by suggesting possible interventions. The 
accompanying text elaborates on the tables’ content. 
Despite substantial efforts, it is impossible to list every 
possible unintended consequence. Bearers could 
have been described and grouped in a more detailed 
manner and there are most likely more possible inter-
ventions than suggested here. Still, this report may 
be a useful starting point for discussing the issue of 
unintended consequences and how to reduce their 
extent and impact. Besides diminishing negative 
impacts on those affected, a successful reduction 
may also increase public support for drug control 
policies and regulations.
Health effects from restricted 
availability of controlled medicines
The purpose of the UN Conventions on Narcotic Drugs 
is dual: first, to prevent any misuse of controlled sub-
stances and second, to guarantee their availability 
for scientific and medical purposes. This implies that 
governments also have a dual obligation to develop 
policies and regulations for preventing possible abuse 
and harms while ensuring the adequate availability for 
scientific purposes and adequate availability, acces-
sibility and affordability for those in need. In practice 
however, many states have mainly focused on control 
and restriction of listed substances, severely impeding 
the availability of controlled medicines for medical 
and scientific purposes. As a result, the implemen-
tation of the conventions in national legislation and 
policies are often much stricter than required by the 
conventions at the cost of patients in need, particularly 
patients in need of pain relief and palliative care and 
opioid dependent drug users seeking treatment (44). 
Table 1 – Health effects from restricted availability of controlled medicines
Mechanisms Unintended Consequences Users 
Non-
users
Possible interventions (PI)
Strict regulations 
and limited access 
to prescription 
drugs, in particular 
morphine and other 
opioid analgesics
Reduced possibilities for 
medical improvements 
related to avoidable pain 
and other symptoms 
for patients in need
Limited availability of opioid 
substitution treatment
Restricted possibilities 
to conduct research on 
medical marihuana 
X
X 
X
X
X
PI 1: Ensure access, availability 
and affordability of controlled 
medicines to patients in need 
PI 2: Ensure inter-agency 
collaboration between all relevant 
stakeholders, government 
and civil society, to promote 
coherent drug policy responses
PI 3: Ensure access to appropriate 
treatment supported by 
adequate psychosocial 
care and rehabilitation
PI 4: Raise awareness and provide 
training for treatment with opioids 
among healthcare professionals
PI 5: Reschedule cannabis
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Strict regulations and limited access 
to prescription drugs
A study conducted by the Access to Opioid Medications 
in Europe (ATOME) group in 12 European countries 
adopting the World Health Organization (WHO)’s 
Country Assessment Checklist reported that a number 
of legal and regulatory barriers exist (45). Findings 
indicate that a range of regulatory barriers exist in 
national legislations related to prescribing, dispensing, 
and using opioid medicines, as well as trade and dis-
tribution, manufacturing, affordability, penalties, and 
language. Additionally, beyond the barriers of national 
legislation, there are also challenges concerning 
national policy strategies, such as lack of knowledge 
and appropriate training of healthcare professionals 
and poorly‐developed health care systems (46). Strict 
regulations and inappropriate policies were found to 
have negative impact on adequate access to opioid 
medicines and severe unintended consequences on 
the lives of those in need of these drugs.
Morphine is considered to be the gold standard for 
treatment of moderate and severe pain (47-49). Since 
1977, morphine has been designated by the WHO 
as an essential medicine, indicating that it should 
be available at all times and at a price that individual 
citizens and communities can afford (50). Still, there 
continues to be a global burden of unrelieved pain. 
The WHO estimates that more than 5.5 billion people 
live in countries with low or no access to controlled 
medicines and have no or insufficient access to treat-
ment for moderate to severe pain.3 Further, there 
are profound inequalities of morphine consump-
tion between high-income countries and low- and 
middle-income countries (51;52). According to the 
International Narcotics Control Board (INCB), a small 
number of high‐income countries consume most of 
the morphine in the world, while countries inhabited 
by 80% of the world’s population consume a small 
fraction (53). The WHO states that one reason for this 
limited access to prescription drugs is due to too strict 
enforcement of the UN Conventions (44).
Further, it is estimated that 16 million people inject 
drugs worldwide and that 5.8 million of these live in 
Europe. Persons who inject drugs (PWID) have a 20-fold 
increased risk of premature mortality and substan-
tially increased risk of severe morbidity (5;54). Opioid 
agonist maintenance treatment (also called opioid 
substitution treatment, OST), combined with psycho-
social assistance, is assumed to be the most effective 
treatment option (5;55-57). Still, only a minority of 
PWID have access to this kind of treatment. Beyond 
3. The countries with low or no access are defined as countries 
where the consumption of opioid analgesics is lower than 
30% of the adequate per capita consumption. The adequate 
consumption is defined as the average per capita consump-
tion in the top 20 countries in the Human Development 
Index.
the benefits of assisting the individual to overcome 
withdrawal, reduce drug use and prevent relapse, 
opioid maintenance treatment contributes to reduced 
risk of overdose-related mortality, transmuting infec-
tions such as HIV and hepatitis (see for review Gowing, 
Farrell, Bornemann, et al. (58)), and a reduction of pub-
lic nuisance and criminality (i.e. Mattick, Breen, Kimber, 
et al. (59)). Despite strong evidence for the efficacy of 
treating opioid dependence with long-acting opioid 
agonists such as oral methadone and buprenorphine, 
it is estimated that only 8% of injecting drug users 
have access to treatment for opioid dependence 
(44). In Europe, the WHO states that in 15 of the 25 
European Union Member States, medical treatment 
with opioids was close to non-existent. This treatment 
gap for drugs and addictive behaviours leads to loss 
of life and undermines societal well-being (60).
Other effects of current laws and enforcement prac-
tices are the formal and informal restrictions on 
research regarding the therapeutic value and efficacy 
of cannabis’ medicinal properties. Various bureaucratic, 
economic and cultural barriers in Europe and other 
developed countries hinder medical research on the 
drug (61). Cannabis is currently defined as a Schedule I 
drug, with a “high potential for abuse and no accepted 
medical value.” To conduct research with Schedule I 
drugs, scientists usually have to gain a special approval 
and upgrade security protocols in their labs, which 
are expensive and time-consuming hurdles. As a 
result, the currently available evidence stems from 
small-scale efficacy studies that have not followed 
gold standard methodologies for assessing medical 
practice. Thus, the effects of therapeutic interventions 
of cannabis and essential knowledge of the drug, 
such as dosage, interactions with other medicines, 
composition, side effects, and for which conditions 
it may be used, remain empirically untested. This 
implies that the current medical use of marihuana is 
based on less than satisfactory evidence and clinical 
standards. The anecdotal evidence supporting the 
use of medical marihuana needs to be confirmed 
by meta-analysis and long term efficacy studies that 
follow standardized methodologies and protocols for 
assessing clinical efficacy, as also stated by “The Health 
effects of cannabis and cannabinoids: The current State 
of Evidence and Recommendations for research” by 
The National Academy of Sciences 2017 (62).
In sum, the too strict interpretation and enforcement 
of the drug conventions affects non-users of illegal 
drugs to a large extent, through insufficient access 
to pain medication and limited research on potential 
beneficial effects of medical marijuana. It also severely 
affects users through reduced access to the most 
promising treatment option for opioid dependence. 
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Possible interventions (PI)
PI 1: Ensure access, availability and affordability of con-
trolled medicines to patients in need
WHO has urged all governments to “ensure that 
patients have pain relief in accordance with national 
and international treatment guidelines” (63). Possible 
responses may include: 
► Implement recommendations in the WHO pol-
icy guideline4 “Ensuring Balance in National 
Policies on Controlled Substances, Guidance 
for Availability and Accessibility for Controlled 
Medicines” (44).
► Ensure non-stigmatizing language in legal 
and official documents (e.g. by using the term 
‘Narcotic drug’ only for referring to substances 
controlled under the Single Convention);
► Establish regular exchange opportunities (com-
munication networks) between legal and gov-
ernmental authorities, healthcare professionals 
and patients/families in order to raise aware-
ness for practical impact and requirements of 
legal and policy decisions (target-performance 
comparison) regarding opioid availability and 
accessibility;
► Provide and support the implementation and 
development of national databases for scientific 
research, treatment evaluation and monitoring 
of national demand of essential medicines
► Raise awareness in the general public, for exam-
ple through media campaigns or information 
and brochures for patients and relatives 
PI 2: Ensure inter-agency collaboration between all rel-
evant stakeholders, government and civil society to 
promote coherent drug control policy responses
In order to formulate and implement coherent drug 
control policies ensuring the availability and accessibil-
ity of controlled substances for medical and scientific 
purposes, increased cooperation among relevant 
4. The World Health Organization (WHO) established in 2007 
the “Access to Controlled Medications Programme” (ACMP) in 
consultation with the International Narcotics Control Board 
(INCB) and in response to resolutions of the World Health 
Assembly (WHA) and the Economic and Social Council of the 
United Nations (ECOSOC) (WHA58.22 and ECOSOC 2005/25)). 
The programme aims at promoting the availability, afford-
ability, accessibility and rational use of controlled medicines; 
it addresses all aspects that act as barriers in obtaining con-
trolled medicines for medical treatment and provides nor-
mative guidance, development and dissemination of interna-
tionally recognized standards for treatment, policy analysis, as 
well as training and support in drafting national action plans 
for improving access to opioid medicines. The ACMP, among 
others, collaborates with the WHO Collaborating Centre for 
Pain and Palliative Care, with the European Association for 
Palliative Care (EAPC), the International Association for Hospice 
and Palliative Care (IAHPC), the International Observatory 
on End of Life Care (IOELC), Human Rights Watch and Harm 
Reduction International (HRI).
stakeholders is recommended. Such cooperation could 
take the form of a National Advisory Board, including 
representatives from government authorities, medi-
cal boards, health professionals, patients and health 
insurances. The board could provide suggestions 
on how to achieve an appropriate balance between 
availability and prevention, assist in conducting the 
needs assessment for controlled medicines and report 
on the degree of access. It could also advise on the 
promotion of rational use of controlled medicines, 
implementation of best practices, and development 
of national treatment guidelines. 
PI 3: Ensure access to appropriate treatment supported 
by adequate psychosocial care and rehabilitation
Given the well-documented effect of opioid substi-
tution treatment (OST) in reducing risks of mortality, 
morbidity, crime and public nuisance, all countries are 
encouraged to provide OST programmes to treatment 
seeking opioid dependents. OST has been found to 
improve treatment retention (64;65), reduce illegal 
drug use (59;66;67), reduce criminal activity (68-70) 
and reduce mortality risk among its patients (56;71-
77). However, evidence-based drug-free treatment 
options should also be provided.
PI 4: Raise awareness and provide training for treatment 
with opioids among practicing healthcare professionals 
All relevant stakeholders and agencies involved in drug 
control (customs officials, police and courts officials) 
and health care providers (doctors, nurses, health 
professionals) should have sufficient knowledge of the 
government’s health policy with regard to treatment 
using controlled medicines. Drug control officials 
should acknowledge when it is lawful for patients and 
health professionals to be in possession of medicines 
and not exert excessive control measures. Physicians 
should be sufficiently trained to treat pain and be 
allowed to prescribe opioid analgesics if necessary. 
Specialized training should be developed for treat-
ment and use of controlled medicines in accordance 
with international guidelines. Treatment with opioids 
(knowledge, skills, attitudes) should be included in 
undergraduate and postgraduate education for all 
relevant healthcare professionals.
PI 5: Improve possibilities for cannabis research
The most effective means for improving pharmacology 
and therapeutics research of cannabis would be to 
reschedule the drug from a Schedule I controlled sub-
stance to a Schedule II, as this is one of the predominant 
factors that prevents many institutions and research 
organizations from conducting research on this topic. 
This is already implemented in some countries, such 
as Israel and the UK. Independent of a reschedule, 
however, an increase in legal access to the drug (more 
legal producers) and a reduction in formal and informal 
restrictions would be beneficial for research. 
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Health effects due to drug prohibition
The creation of a “black market” for illegal substances 
is one example of an unintended, although not unex-
pected, effect of the ban on drugs. This unlawfulness 
is likely to have consequences for the types, prices and 
qualities of the goods offered on the illegal market 
and may also cause stigmatization and negative social 
effects, all of which may lead to adverse effects on 
users’ health. 
 Table 2 – Health effects due to enforcement of drug prohibition 
Mechanisms Unintended Consequences Users
Non-
users
Possible interventions (PI)
Substance 
displacement to 
more hazardous 
but “legal” drugs
Increased health risk 
due to unknown, often 
dangerous and potentially 
lethal substances 
X PI 6: Develop prevention 
strategies: raise awareness, 
provide relevant information, 
education and communication 
targeting relevant groups 
PI 7: Develop regulations for 
NPS that take into account 
unintended consequences 
 PI 8: Strengthen links 
between government bodies 
and civil society actors
PI 9: Set up system for information 
exchange between countries 
on latest developments and 
practiced responses
Elevated drug price Increased risks of unsafe 
drug use (e.g. injecting)
Less disposable income 
for food, health care, 
clothing, housing etc. 
X
X
PI 6: (see above)
PI 10: Increase capacities and 
upgrade current practices of 
low-threshold services5
PI 11: Encourage peer-to-peer 
training and outreach work
Variation in purity Increased risks of 
mortality and morbidity
X PI 6, PI 10, PI 11
PI 12: Ensure effective Naloxone 
distribution to medical 
and emergency services to 
prevent lethal overdosing
Stigmatization Discourages users from 
seeking help and support
May lead to negative 
attitudes of health 
care providers 
Loss of self-esteem, 
impaired well-being of 
users and their associates.
X
X
X X
PI 13: Ensure participation of drug 
users in community and social life 
and ensure that their views are 
taken into account in decision-
making on relevant issues 
PI 14: Implement anti-
discrimination campaigns and 
provide specialised training to 
health care and social workers
5. Including, but not limited to, scaling up Needle and Syringe Programs (NSP); Supervised drug consumption facilities (SDCF) 
Community-based outreach programs (CBO); Opioid substitution treatment (OST) and other drug treatments; Antiretroviral therapy 
(ART); Vaccination, diagnosis and treatment of viral hepatitis.
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Substance displacement to more 
hazardous but “legal” drugs 
One unintended consequence of the illegal status and 
law enforcement practices against certain drugs is 
substance displacement, where the control of one sub-
stance causes suppliers and users to move to another 
drug with similar effects but with fewer regulations 
attached (the so-called “balloon effect”). Drug suppli-
ers, in an effort to avoid drug control and ameliorate 
the damages and losses related to law enforcement, 
design chemical compounds (“legal highs”) that mimic 
banned substances such as cannabis or cocaine; a 
small variation in the chemical structure of a banned 
drug can make them fall outside international drug 
control regulations. 
In 2015, 100 new psychoactive substances (NPS) were 
reported for the first time to the EU Early Warning 
System (EWS), bringing the total number of moni-
tored substances to 560 – with more than 380 (70%) 
of these detected in the last five years alone (5). The 
unprecedented emergence of these substances with 
unfamiliar compounds and unknown potency and 
toxicity has been related to an extensive list of harmful 
effects, including emergency room admissions and 
fatalities, increased overdoses, high tolerance, and 
withdrawal symptoms and dependence-producing 
properties (78). 
Possible interventions (PI)
 PI 6: Develop prevention strategies: Raising awareness, 
providing information, education and communication 
targeting relevant groups
Interventions may include targeted information, edu-
cation and communication (IEC) to NPS users. IEC 
activities can include promoting reduced risk-taking 
and enhanced self-protection, improving care and 
management of medical crises such as overdose, 
influencing sub-cultural norms and attitudes in a more 
risk-reducing direction, and informing users about 
available health and social services and encouraging 
them to seek treatment. Awareness-raising campaign 
needs to be conducted on a systematic basis. These 
campaigns should be targeted, adequately resourced, 
and expanded and promoted if they are to meet 
their full potential and adequately protect children 
and young people from the harms associated with 
NPS intake. 
Currently, there is limited knowledge of NPS use and 
user profiles. Early detection, screening and assess-
ment strategies targeting NPS use are lacking in many 
countries (79). Due to this, identification of specific 
subgroups of young people that are especially vul-
nerable for drug use is becoming an important tool 
for directing or channelling policy responses and 
facilitating the development of effective interventions. 
PI 7: Development of regulations for NPS that take into 
account unintended consequences
Many governments have developed prohibitive leg-
islation to control NPS, targeting suppliers and deal-
ers of these substances. Following the model of the 
international drug control conventions, individual 
substances are controlled once their harm has been 
assessed. They are often divided into schedules/lists 
that classify them individually based on medical use, 
their relative abuse potential, and their likelihood of 
causing dependence when abused. However, the 
legislative process associated with placing new sub-
stances under drug control legislation is often lengthy 
and may produce a prolonged time lag between NPS 
identification and implementation of control measures. 
Furthermore, there is limited scientific evidence on 
NPS toxicity, abuse liability and risks associated with 
long term intake. Additionally, these substances are 
often hard to identify due to their diverse branding and 
inconsistent product composition, which creates major 
challenges for developing effective policy responses. 
One approach has been to schedule new substances 
into existing drug control laws or into other forms of 
legislation, such as consumer or health protection and 
trading standards legislation. However, as legislation 
in many countries requires strict and precise identifica-
tion of every controlled drug, illegal producers aim to 
avoid control by continuously introducing “new,” but 
very similar products. This has in some cases resulted 
in a “cat & mouse” game between producers and 
enforcement agencies (80). As a response, legislators in 
some jurisdictions have introduce a so-called generic 
legislation, in which clusters of psychotropic drugs are 
banned preemptively. Yet, generic legislation may also 
result in unintended consequences and the search 
for an optimal response to NPS should be prioritized. 
PI 8: Strengthen links between government bodies and 
civil society actors to exchange knowledge, existing 
practice and cooperation in joint action
An integrative community based system is one that 
develops synergies with local civil society organi-
zations (CSOs), physicians, hospitals and demand 
reduction and health-promoting services of the gov-
ernment. Integration of these actors may increase 
the likelihood of successful implementation, increase 
service efficiency and reduce public expenditure, as 
it can provide a more comprehensive array of service 
responses that are aligned with individual needs 
and make use of the already available community 
resources and infrastructure (81).
PI 9: Improve the systems for information exchange 
between countries on latest developments and practice 
responses
The increasing prevalence of new psychoactive sub-
stances around the world poses serious cross-border 
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threats to health, which makes it necessary to enhance 
monitoring, early warning and responding. Early warn-
ing systems and networks are tools to identify poten-
tial threats, review new and existing legislation, and 
provide the basis for decision-making for temporary 
restriction measures. Improved information exchange 
and international forums for discussion of proposed 
enforcement initiatives, prevention measures and 
treatment strategies based on contextualized needs 
would be useful. 
Some early warning systems already exist, such as the 
Early Warning Advisory (EWA) of the UNODC and the 
Early Warning System (EWS) of the EU. Still, strength-
ened systems, which manage to reduce the time span 
from the emergence of a new substance to a societal 
response, are needed. These systems could further 
boost the exchange of information among states to 
help them anticipate a potential public health threat, 
with a clear added value of alerting other states to 
potentially harmful substances that have emerged. 
Elevated drug price 
Drug producers and sellers want economic com-
pensation for their costs and for the risks they face 
(risks for apprehension, violence, incarceration, etc.) 
when making an illegal commodity available to drug 
consumers. This leads to an elevated price level of 
illegal drugs. Increased prices usually lead to reduced 
consumption and is, as such, an intended effect of the 
drug policy. The high price level, however, may also 
induce some drug users to change their mode of drug 
administration. For instance, users may change from 
smoking or snorting heroin to drug injecting, as injec-
tion is a more cost-effective mode of consumption. 
Drug injection, however, is highly associated with an 
increased risk of premature mortality, communicable 
diseases and a range of other health-related problems. 
Higher prices may also change the types of drugs that 
users consume. As mentioned above, drug producers 
have designed cheap synthetic drugs that mimic the 
desirable effects of well-known substances. This means 
that the high price level may cause an increase in 
health risks due to consumption of unknown, often 
dangerous and life-threatening synthetic drugs. 
Finally, the high price level often implies that drug 
users, and especially problem drug users, spend a 
large share of their income on supporting their habit. 
Beyond the association with higher rates of income 
generating crime that will be discussed later in more 
detail, the elevated price level will reduce the money 
available for important commodities such as hygiene 
articles, food, clothing, shelter, and health care, nega-
tively impacting drug users’ health and quality of life.
Possible interventions (PI)
 PI 6: Introduce, or expand, targeted information, edu-
cation and communication (IEC) to drug users 
As mentioned above, IEC activities towards drug 
users can include promoting reduced risk-taking and 
enhance self-protection, improving care and man-
agement of medical crises such as overdose, shaping 
sub-cultural norms, and informing users about avail-
able health and social services and encouraging them 
to seek treatment.
PI 10: Increase capacities and upgrade current practices 
of low-threshold services to respond more effectively to 
drug users’ health and social needs, including interven-
tions tailored to PWID 
► Treatment programs, whether opioid substi-
tution or drug-free treatment, will contribute 
to reducing negative consequences of elevated 
drug prices on drug injecting. 
► Needle and Syringe Programs (NSP) aim to 
reduce the spread of infectious diseases such 
as HIV and hepatitis C among people who inject 
drugs (PWID). They often provide a range of 
services, in addition to offering sterile injecting 
equipment, including providing health informa-
tion, education on drug use reduction, referrals 
for drug treatment, medical care and legal and 
social services. A review of 200 studies con-
ducted by the WHO suggests that increasing 
the availability and utilization of sterile injecting 
equipment by PWID could reduce HIV infection 
substantially and that these programmes are 
cost-effective and have additional and worth-
while benefits apart from reducing HIV infection 
(82). These programmes may also be beneficial 
to non-users through reduced risk of sex-in-
duced HIV transmission as they provide free 
condoms and safer-sex education.
► Community-based outreach programmes 
(COP) aim to obtain face-to-face contact with 
drug users, provide education on HIV risk-re-
duction, distribute condoms and bleach for 
disinfection of needles and syringes, promote 
referrals to other health services, improve access 
to risk assessment and HIV testing, and provide 
counselling and support community organising. 
Evidence indicates that outreach programmes 
are associated with reduced injection frequency 
and cessation of injecting, reduced reuse of nee-
dles and syringes, needle disinfection, increased 
condom use and reduction in unprotected sex 
and increased entry into drug treatment (83). 
► Supervised Drug Consumption Facilities 
(SDCF) provide safe and hygienic environ-
ments for drug use. They are associated with 
reduced public order and nuisance problems 
and improved health for PWID through reduced 
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risk behaviour and their role as a gateway to 
other health care services (84). Still, SDCF are not 
sufficiently implemented, or are non-existent, 
in many EU countries. 
► Vaccination, diagnosis and treatment of HIV, 
viral hepatitis and tuberculosis (TB). HIV, viral 
hepatitis and TB among drug users present a 
major health concern. Access to HIV, hepatitis 
and TB prevention, treatment, care and support 
is fundamental for realizing the universal right 
to health. Programmes such as antiretroviral 
therapy (ART) have the potential to reduce 
mortality and morbidity rates among infected 
people, improve their quality of life, act as a 
post-exposure prophylaxis (85) and prevent 
further transmission of HIV infection (86;87).
PI 11: Encourage peer-to-peer training and outreach work
Peer-training focusing on early involvement of emer-
gency services, measures to access and use first aid, 
and means to reduce the risk for drug-related deaths 
should be encouraged and helped. Drug users’ involve-
ment can be an important peer-based education com-
ponent for effective outreach interventions because 
peers can help to change social norms through edu-
cation and by demonstrating changes in their own 
behaviour (88). Individuals who use drugs have valu-
able knowledge of drug use practices and patterns 
and are often able to help identify the most effective 
ways to reduce the spread of blood borne disease and 
to assist peers in other ways (89). 
Acknowledging the fact that in most overdose cases 
other peer-users are the only witnesses (90), a set of 
peer-delivered first aid practice should be designed 
and promoted. These may include training on over-
dose prevention and response techniques for peers 
that may serve to improve peer-delivered first aid 
(91), campaigns to encourage drug users to call emer-
gency services, training and information concerning 
overdose prevention and its management (training 
in the recovery position and CPR). One particular 
area in which peer-to-peer training is likely to be of 
significance is Naloxone distribution, as highlighted 
in a systematic review by the EMCDDA (92). Naloxone 
peer-programmes should include identifying and 
responding to opioid overdoses and essential first aid 
training. Most peer-training programmes included 
didactic and interactive components, opioid symp-
tom recognition, response training and contacting 
emergency medical service. See PI 12 below for more 
details regarding Naloxone programmes.
Variation in purity
Given the illegal production and dealing of controlled 
substances and the lack of standardization and quality 
control, there is substantial variation in drug purity 
and samples are sometimes contaminated by toxic 
ingredients. This implies an increased risk of morbidity 
and premature mortality, and fatalities have risen in 
connection with contaminated heroin, scopolamine 
poisoning, PMA within ‘ecstasy’ tablets and clostrid-
ium infections such as botulism (Bargagli et al. (93); 
Degenhardt et al. (54); EMCDDA (94;95)). 
Possible interventions (PI) 
PI 6: Introduce, or expand, targeted information, educa-
tion and communication (IEC) to drug users 
PI 10: Increase capacities and upgrade current practices 
of low-threshold services to respond more effectively to 
drug users’ health and social need, including interven-
tions tailored to PWID 
PI 11: Encourage peer-to-peer preventive work
PI 12: Ensure effective Naloxone distribution to medical 
and emergency services to prevent lethal overdosing
The majority of drug-induced deaths are caused by 
the intake of opioids such as heroin and methadone 
(96); consuming these drugs by means of injection 
increases the risk of premature mortality. Naloxone 
is an opioid antagonist, which blocks the actions of 
opioid medicines and has long been used in the emer-
gency treatment of opioid overdose (97). It counteracts 
the depressive respiratory effects of opioids and can 
bring an overdose patient back to consciousness 
within minutes following its administration. Despite 
WHO guidelines (98) and its recommendations for 
available naloxone ws for reducing the mortality rates, 
the antidote is currently available in less than a third 
of the 28 EU Member States (5). Action is urgently 
needed to improve take-home naloxone availability. 
Education and training for healthcare professionals, 
drug users and laymen concerning administration of 
naloxone are necessary. Drug workers should receive 
updated overdose information and training as part of 
their continuous professional development. Providing 
naloxone kits to laypersons reduces overdose deaths 
(99), is safe (100), and is cost-effective (101). The US 
and international health organizations recommend 
providing naloxone kits to laypersons who might 
witness an opioid overdose, to patients in substance 
use treatment programs, to persons leaving prison 
and jail, and as a component of responsible opioid 
prescribing (98;102).
Health effects of stigmatization 
Individuals who are discriminated against because of 
preconceived judgments based on their appearance, 
disabilities or lifestyle are victims of stigmatization. 
Drug users often experience stigmatization in terms 
of marginalization and social exclusion. Stigmatization 
harms individuals’ self-esteem and well-being. Drug 
users may experience reduced access to health and 
social services because of the stigmatization related 
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to their drug use and discrimination may hinder treat-
ment seeking and service utilization. 
According to the WHO many people with drug use 
disorders do not receive effective treatment and care 
(103). Until recently, drug dependence has not been 
recognized as a health problem in society at large, 
and stigma and discrimination associated with drug 
dependence have become major barriers to appro-
priate treatment. Governments should, as a matter of 
policy priority, identify and provide equitable medical 
care and social assistance to all in need, particularly to 
vulnerable individuals and groups facing exclusion. 
This can be achieved by adjusting or developing 
clearly formulated treatment guidelines.
Furthermore, stigmatizing attitudes towards people 
who use drugs may also exist among staff in health-
care services. This can be a barrier for access to, and 
deliverance of, effective treatment for drug users and 
further stigmatize individuals with drug use problems 
or with health problems such as hepatitis and HIV 
infection (104;105). Studies have identified that some 
health-care providers hold negative beliefs about 
drug users, for example that they overuse health care 
resources, do not invest in their own health, abuse the 
health care system through drug-seeking and diver-
sion and fail to adhere to recommended treatment 
and care (106). 
Stigmatization may also affect the health of non-users 
in terms of marginalization and social exclusion of 
drug users’ next of kin. Children, parents, partners and 
friends of drug users may experience health problems 
as a result and they may be discouraged from seeking 
adequate help from health care services and providers.
Possible interventions (PI)
PI 13: Ensure participation of drug users in community 
and social life and ensure that their views are taken into 
account in decision-making
In the development and implementation of drug 
policies at the national and international level, active 
and meaningful involvement of civil society, non-gov-
ernmental organizations and people who use drugs 
should be requested. Governments are encouraged 
to support the initiatives of people who use illegal 
drugs and provide supporting mechanisms for active 
involvement of drug users in the decision-making 
process, program development, implementation, and 
evaluation of drug-related interventions. 
PI 14: Implement anti-discrimination campaigns and 
specialized training for health care, justice and law 
enforcement 
To foster diversity and anti-discrimination policies, 
increase knowledge, understanding and respect 
for human rights, and encourage social inclusion of 
individuals with drug use problems, authorities are 
encouraged to develop public campaigns. The goal 
of this is to raise public awareness and expand the 
knowledge base on harmful consequences of stig-
matization and discrimination, strengthen vulnerable 
groups’ human rights, and encourage citizens’ active 
engagement. Additionally, this would foster a dialogue 
on the effects of current policies on individuals’ health, 
rights and safety (107). Authorities are also encour-
aged to develop targeted specialized trainings and 
academic curricula for those working at the forefront. 
This may include people in health care (doctors, nurses, 
social workers), the justice sector (judges, prosecutors, 
administrative staff) and law enforcement. 
Health effects resulting from 
enforcement actions 
Some unintended effects are caused by the legal ban 
substances, while others are caused by the method in 
which drug laws are enforced. Drug control actions, 
such as arrests, border controls, and ID-checks of sus-
pected drug offenders, imply direct and face-to-face 
contact between law enforcement agents, the general 
public and people involved with drugs. Maintaining 
the balance between enforcing laws and protecting 
rights and health of individuals, including drug users, 
is demanding and challenging. Law enforcement offi-
cers are constantly confronted with these challenges 
in their daily practice. While being an important and 
necessary part of the drug control, these actions 
may also lead to some severe, unintended health 
consequences. 
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Table 3 – Health effects resulting from enforcement actions
Mechanisms Unintended Consequences Users
Non-
users
Possible interventions (PI)
Counter-acting 
effects on health 
and utilisation of 
health care and harm 
reduction services
Increase the risk for:
– Deterioration of 
health status 
– Spread of HIV/AIDS 
and other infectious 
diseases for drug users 
and their sex-partners
– Users abandoning 
other users in need of 
emergency aid due to 
fear of apprehension
X
X 
X
X 
X
PI 6, PI 10, PI 11, PI 12
PI 15: Include psychosocial 
support and preventive harm 
reduction practices in training 
curricula for prison personnel 
and police services 
PI 16: Implement community based 
policing and prevention programs 
PI 17: Develop and implement 
police service performance 
indicators based on public 
safety and health objectives 
PI 18: Introduce referral schemes 
for available treatment and 
low threshold services
PI 19: Encourage witnesses to call 
health agencies for users in need
PI 20: Set up a centralized 
database for systematic 
monitoring of specific needs of 
different drug user groups
Physical contact 
between law 
enforcement agents 
and suspects of 
drug law offenders
Risk of inappropriate 
use of force, violation of 
rights, physical and mental 
harms and distress
X
X
PI 15, PI 16, PI 17
PI 21: Implement mechanisms 
for accountability for law 
enforcement officers 
PI 22: Develop independent and 
transparent complaint mechanisms
Barriers to 
implementing 
appropriate 
treatment and low-
threshold services 
in detention (prison, 
pre-trial detention, 
police custody, etc.) 
Increased risk of health 
problems such as HIV/AIDS, 
Hepatitis C, tuberculosis and 
other infectious diseases
X X PI 23: Provide relevant treatment 
and rehabilitation services in 
prisons, detention and facilities 
for refugees and immigrants
PI 24: Facilitate adequate 
vaccination programs and 
prophylactic measures to drug 
users and their associates
Counter-acting effects on health and 
utilisation of services
In recent years, studies have examined the potential 
impact of police presence on drug users’ access to 
health services. They suggest that periods of intensi-
fied police activity are associated with reluctance of 
PWID and other drug users to seek medical assistance 
out of fear of arrest, as well as and decreased atten-
dance at voluntary treatment programs and needle 
exchange services (108-111). This may seriously affect 
drug users’ health and social wellbeing. 
Police activity has also been associated with increased 
syringe sharing among PWID. Despite research find-
ings which indicate that access to sterile syringes is 
a key factor in preventing the spread of HIV (112), 
police arrests and confiscation may in some countries 
prevent PWID from approaching these services or 
to carry safe injection and bleach kits (110;111;113-
116). Further, in some cases, police have destroyed 
injecting equipment or forced drug users to throw 
them away (117). There are also studies suggesting 
that injecting drug users are forced to modify their 
injection practices in an effort to consume the drug 
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before police confiscate it. Studies indicate that PWID 
are more likely to share injection equipment due to 
the rush and fear of being caught by police and are 
less likely to clean injection sites prior to injection or to 
dress wounds afterward. This rush during the admin-
istration process often means skipping important 
steps of the preparation phase (118); drugs may be 
mixed without first being heated to kill bacteria and 
filtered to remove impurities (119). Rushing may also 
increase risk for vascular damage (120) and overdose 
since the drugs are injected quickly and not tested 
for strength first.
Further, displacement of drug users to new neigh-
bourhoods is sometimes a result of police interven-
tions. This may lead to an increase in public injecting, 
unsafe syringe disposal (121-124) and increased risk of 
infectious diseases, which may in turn threaten both 
community cohesion and public health. In the US 
and Europe, displacement often generates a so-called 
“shooting gallery” (125). Without sufficient access to 
health promoting services providing clean injection 
equipment and other necessary items, displacement 
increases the risk of infectious diseases and premature 
mortality (126-131). The spread of HIV and other blood 
borne diseases is also a threat to non-users. Relatives, 
partners, friends, sex-trade clients, health personnel 
and others in regular contact with PWID run a risk of 
being infected. 
Possible interventions (PI) 
PI 6: Develop prevention strategies: raise awareness, 
provide relevant information, education and commu-
nication targeting relevant groups
PI 10: Increase capacities and upgrade current practices 
of low-threshold services to respond more effectively to 
drug users’ health and social needs,6 including interven-
tions tailored to NPS users 
PI 11: Encourage peer-to-peer work, and promote 
peer-training in outreach work, including measures to 
reduce drug-related deaths, early involvement of emer-
gency services, and measures to access and use first aid
PI 12: Ensure effective Naloxone distribution to medical 
and emergency services to prevent lethal overdosing
PI 15: Include psychosocial support and preventive harm 
reduction practices in training curricula for prison per-
sonnel and police services 
Although police work has traditionally played a funda-
mental role in supply reduction, there is an increasing 
awareness that police also may also play a major role 
6. Including, but not limited to, scaling up Needle and Syringe 
Programs (NSP); Supervised drug consumption facilities 
(SDCF) Community-based outreach programs (CBO); Opioid 
maintenance therapy (OMT) and other drug treatments; 
Antiretroviral therapy (ART); Vaccination, diagnosis and 
treatment of viral hepatitis.
and actively participate in effective implementation of 
health promoting strategies. As gatekeepers between 
the criminal justice system and the broader commu-
nity, police can act as a regulatory mechanism and 
coordinate programs that aim to reduce drug-related 
harm to individuals and communities. Police can refer 
people to drug treatment agencies or other types of 
assistance, act as a useful resource for drug education 
programmes and provide a supportive environment 
for needle exchange programmes by not targeting 
the vicinity around these programmes to arrest users. 
In order to better equip law enforcement officials for 
their important role in public health and increase their 
awareness of the health and welfare implications of their 
actions, different levels of specialized harm reduction 
training are required. Training can be incorporated in 
academia with a standardized curriculum for different 
law enforcement fields. Best practice training manuals 
and guidelines for law enforcement officials should be 
developed based on the available evidence on health 
promoting interventions. These may include topics such 
as the impact and contribution of law enforcement on 
public health and human rights, referral pathways and 
integrative care with cross-agency collaboration and 
synergies with health services and CSOs, and quality 
assurance and regular information updates.
PI 16: Implement community-based policing and pre-
vention programs 
Community-Based Policing (CBP) is a strategic initia-
tive that focuses on police building ties and synergies 
with members of the community. It is designed to 
support active collaboration between law authorities 
and local communities by enhancing their capacity 
and competency to effectively respond collaboratively 
to contemporary challenges. CBP represents a collab-
orative model for the reduction of adverse mental 
health, drug- and crime-related consequences, by using 
community-based assets that make efficacious use of 
available resources to meet identified needs within a 
framework that promotes sustainable and place-spe-
cific interventions (132). CBP personnel adopt a dual 
role as both police officers and social agents. As police 
officers, they maintain public tranquillity, law and order, 
protect individuals’ fundamental rights and freedoms, 
prevent and detect crime, and reduce fear. As social 
agents, they may provide assistance and services to 
the public, harm reduction and treatment referrals, 
deliver naloxone to an overdose case or participate in 
local health campaigns, and promote healthy life styles.
This mutually-beneficial partnership with grassroots 
community resources (multidisciplinary partnerships 
with community organizations, other government 
agencies, non-profit and SCOs, businesses, the media, 
and individual organisations), advances the capacity 
to adequately respond to current challenges and 
strengthen community resilience. 
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PI 17: Develop and implement police service performance 
indicators based on public safety and health objectives 
The development and implementation of performance 
indicators for police services based on objectives 
beyond traditional police work, such as clearance rate, 
could facilitate and complement public health goals, 
as law enforcement agents would be a supplemen-
tary component in addressing the health and social 
needs of vulnerable populations. This involves moving 
away from simplistic metrics such as numbers of drug 
related arrests, drug seizures and hectares of drug 
crops eradicated towards indicators of community 
health and wellbeing, such as reductions in mar-
ket related violence and corruption, improvements 
in public health and economic development, and 
strengthening of community institutions. Police ser-
vice performance indicators should, when possible, 
support the broader agenda of public health.
PI 18: Introduce referral schemes to available treatment 
and low threshold services
Drug Referral Schemes (DRS) are partnerships between 
police and local drug services that use an arrest as 
an opportunity for independent drug workers to 
offer arrestees help and refer them to appropriate 
treatment services, primarily as a means for reducing 
their drug-related offences. In addition, they may 
also provide a route to HIV testing and counselling 
services, antiretroviral therapy (ART), prevention and 
treatment of sexually transmitted infections (STIs), 
vaccination, diagnosis and treatment of viral hepatitis, 
and prevention, diagnosis and treatment of tubercu-
losis (TB). DRS allow specially trained drug workers 
(known as drug/arrest referral workers) to contact 
arrestees while they are held in police custody and 
grant them sufficient time to interview the arrestee 
and complete a ‘needs assessment’ form, which will 
be the basis of a treatment and care plan.
PI 19: Encourage witnesses to call health agencies for 
users in need
Police can avoid arrests at the scene of a drug over-
dose and by doing this, encourage people to call for 
medical help without delay or fear of prosecution. 
Drug users should also be able to call ambulance and 
health services anonymously. 
PI 20: Set up a centralized database for systematic moni-
toring of specific health needs of different drug user groups
The risks of harmful consequences of substance use 
vary substantially depending on the type of substance 
and pattern of use, including frequency, amount and 
concurrent use of several drugs. Knowledge of the 
quantitative and qualitative patterns of drug use is 
a key element for the development of drug policies 
tailored to high-risk subgroups, their individual needs 
and the contextual demands. At the European level, 
substance use monitoring is based on procedures 
organized by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) for illegal drugs 
and by the European Medicines Agency (EMA) for pre-
scription drugs, in the context of pharmacovigilance. 
In addition to information on user groups and their 
using patterns, an integrative system for assessing the 
potential for abuse of various psychoactive substances, 
as well as the consequences of that use in terms of 
morbidity and mortality, is needed. 
A centralized surveillance system would be helpful 
for developing policies tailored to individuals’ needs 
and contextual demands and to assess the impact of 
measures for minimizing the risk of abuse. 
Physical contact between law 
enforcement agents and suspects 
of drug law offenders 
Practical policing and physical contact between law 
enforcement agents and suspected drug law offenders 
presents a risk of inappropriate use of force, violation 
of human rights, as well as physical and mental harm 
and distress. Each of these elements is likely to have 
adverse health effects for victims (133). Violence and 
excessive use of force against drug users have been 
reported in various regions (134-138),as have human 
rights violations, including extortion of suspected 
drug users, forced detoxification and mandatory HIV 
testing (139;140).
Possible interventions (PI) 
PI 15: Include psychosocial support and preventive harm 
reduction practices in training curricula for prison per-
sonnel and police services 
PI 16: Implement community -based policing and pre-
vention programs 
PI 17: Develop and implement police service performance 
indicators based on public safety and health objectives 
PI 21: Implement mechanisms for police accountability 
and make them visible
Police and law enforcement agencies are the most 
visible manifestation of government authority. The 
United Nations has articulated a set of principles 
for police agencies that included applying the law 
equally to all citizens, guidance on the use of force, 
guarantees of safety and fair treatment of persons 
detained or arrested, allowing the community to hold 
law enforcement officials accountable for their actions, 
and protecting the rights of women, juveniles, and 
refugees (141). Democratic policing requires that the 
police consider themselves accountable to citizens, 
their representatives, the State and the law.
Police services should have their powers checked and 
controlled by the public through accountability pro-
cesses, and “efficient measures to ensure the integrity 
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and proper performance of police staff” need to be 
developed. Performance evaluation and accountability 
reports are likely to be important tools for police exec-
utives in assessing and responding to claims of racial 
bias, patterns of abusive behaviour, or failure to protect. 
PI 22: Develop independent and transparent civilian 
complaint mechanisms 
The existence of a citizen oversight body with respon-
sibilities for handling complaints against the police is 
a core accountability and transparency requirement 
and a prerequisite in a democratic environment. A 
standard statutory purpose, in jurisdictions where 
police complaints systems have been codified, is to 
hold law enforcement officials accountable in criminal 
and disciplinary proceedings on the basis of evidence 
obtained in the investigation of a complaint (142).
An effective police complaints system may reduce the 
risk for the development of a culture of impunity. A 
complaints system serves as a means by which police, 
prosecutors and courts identify acts, and omissions, of 
criminal behaviour, misconduct and below standard 
performance on the part of law enforcement officials. 
Cultures of impunity are liable to develop as a result 
of the failure of police managers, prosecutors and 
courts to take appropriate action against an officer, 
on one hand, or the reluctance of citizens to complain 
because of their lack of confidence in the complaints 
system, on the other hand. Oversight institutions may 
include the executive (policy control, financial control 
and horizontal oversight by government agencies), 
the legislature (members of parliament, parliamen-
tary commissions of enquiry), the judiciary, as well as 
human rights commissions, civilian complaint review 
boards or independent ombudspersons. Furthermore, 
the media can play an important role in providing the 
public with information on police activities. 
Barriers to implementing harm 
reduction programs in custodial settings
In many countries, drug-related offences represent one 
of the main reasons for imprisonment and drug users 
constitute a large share of the prison population (13). 
Although some prisoners stop or reduce their use of 
drugs upon entry in prison, others initiate drug use or 
engage in more damaging behaviours when they are 
incarcerated (143). Drug use and injection often contin-
ues while imprisoned. Additionally, interventions that 
have reduced injection and injection-related health 
risks in community settings often remain unavailable 
in prison (144;145). Access to sterile syringes is often 
extremely limited. Research suggests that 50% or more 
of drug users report injection while in prison (146-148), 
and a substantial proportion of inmates injecting 
drugs engage in needle and syringe sharing during 
imprisonment. Needle and syringe sharing increases 
the risk for transmuting infections and health related 
problems such as vein injury, scarring, and bacterial 
and viral infections. Worldwide, levels of HIV prevalence 
within inmate populations tend to be much higher 
than in the general population (149). 
Further, discontinuation of treatment due to incarcer-
ation or following incarceration may lead to severe 
health consequences for sentenced offenders. These 
consequences result either from the non-availability 
of treatment options in custodial settings for inmates 
who have been in treatment prior to incarceration, or 
as a result of not being able to continue treatment 
following release. The discontinuation of treatment 
following release can lead to the use of street drugs 
again, resulting in a high risk of overdosing and death. 
The same risks exists vice-versa when prisoners cannot 
continue treatment in prison. Additional risks may 
be incurred in short-term incarceration, including 
police arrest and pre-trial detention, where often 
no adequate treatment options are provided (150). 
A principal problem in this respect is inadequate, or 
lack of, coordination and cooperation between prison 
health systems and public health systems outside 
prisons. Often health care in prison settings operates 
in complete isolation from the general health care 
system, hampering the quality and continuation of 
health care following release. This may lead to delays 
in referral for treatment, and as a result, necessary 
continuation of care is not ensured. In addition, a lack 
of adequate healthcare services in prisons significantly 
hinders the social reintegration of prisoners, while 
leading to the spread of transmissible and life-threat-
ening diseases in prisons and the community (151).
The United Nations basic principles for the treatment 
of prisoners recognize that “prisoners shall have access 
to the health services available in the country without 
discrimination on the grounds of their legal situation” 
(United Nations General Assembly, 1990). 7 Still, in many 
EU countries, authorities are reluctant to implement 
harm reduction programs in settings like prisons or 
detention centres. This predisposes marginalized 
groups to an increased risk for HIV/AIDS and other 
infectious diseases, as they are then excluded from pub-
lic health interventions and services. Lack of access and 
availability of health care and harm reduction services 
in prisons raises serious ethical and moral concerns. 
7. United Nations standard minimum rules for the treatment of 
prisoners (152) and United Nations rules for the treatment of 
women prisoners and non-custodial measures for women 
offenders (the Bangkok Rules) (153). The revised Guideline 
6 of the United Nations International guidelines on HIV/
AIDS and human rights (154) states that States should “take 
measures necessary to ensure for all persons, on a sustained 
and equal basis, the availability and accessibility of quality 
goods, services and information for HIV/AIDS prevention”. 
The World Health Organization (WHO) 1993 Guidelines on 
HIV infection and AIDS in prisons state (155): “In countries 
where clean syringes and needles are made available to 
injecting drug users in the community, consideration should 
be given to providing clean injecting equipment during 
detention and on release to prisoners who request this.”
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Further, introducing harm reduction and health promot-
ing measures in prisons also protect the public, as most 
inmates are in prison only for relatively short periods 
of time and are then released into their communities. 
HIV/AIDS prevention and harm-reduction measures 
will also protect the general population, while denied 
access will put non-users at risk for these harms. 
Possible interventions (PI)
PI 23: Provide relevant treatment and rehabilitation 
services in prisons, detention and facilities for refugees 
and immigrants 
As recommended by the WHO, UNODC and UNAIDS, 
governments may introduce, or expand, syringe and 
needle exchange programs (NSP) in order to avoid 
and prevent the threat of HIV epidemic among pris-
oners who inject drugs. Prisoners should have easy, 
confidential access to NSP, and prisoners and staff 
should receive information and education about 
the programmes and be involved in their design 
and implementation. This should not undermine or 
impede the provision of drug dependence treatment 
programmes, including OST, but act as complementary 
intervention safeguarding drug users’ health status. 
Governments could introduce OST in the prison health 
strategy as it provides an opportunity for prisoners 
to avoid needle use and syringe sharing.
PI 24: Facilitate adequate vaccination programs and 
prophylactic measures to drug users and their associates
Vaccination is recommended for people where expo-
sure to body fluids or contaminated devices may occur, 
including health care workers, people who inject drugs, 
men who have sex with men, incarcerated people, 
people with a history of sexually transmitted infection, 
and people who have unprotected sex (156). HBV vacci-
nations can significantly reduce the chance of infection 
(157) and offer protection against infection for more 
than 90% of healthy individuals (158). According to 
the International Standards for the Treatment of Drug 
Use Disorders by UNODC and WHO (159), treatment 
services should offer hepatitis B vaccinations to all opi-
oid-dependent patients. However, in many countries, 
only limited efforts have been made for the practical 
implementation of hepatitis B vaccines. Currently no 
vaccinations exist against HIV or HCV. 
Effects of high profit margins and 
price levels of illegal drugs
The UNODC estimates that illegal drugs account for 
approximately 20% of global crime proceeds and are 
equivalent to about 0.6–0.9% of global gross domes-
tic product (160). In 2013, the retail market for illicit 
drugs in the EU is estimated to have been worth, at 
minimum, EUR 24 billion (11). The drug market is con-
stantly developing and adapting to emerging trends 
and technical innovations. In recent years, illegal drug 
markets have also been found on Internet-based 
platforms. Some Internet sales take place through 
open surface websites, while other transactions are 
made through the “darknet”, an encrypted part of 
the Internet (11). When coupled with the use of cryp-
to-currencies, both dealers and buyers are difficult to 
identify and locate for legal authorities.
Illegal profits flow outside regular financial systems and 
are therefore exempt from financial control, account-
ability, and taxation. The development of illegal markets 
thus has wide-ranging consequences for society and for 
individuals, as it affects the legal economy, national and 
international security, governmental institutions and 
society at large. Further, the high price level of illegal 
drugs has consequences for drug users as it makes it 
harder to support their habit through legal means. 
Table 4 – Non-health effects of illegal drug trade 
Mechanisms Unintended Consequences Users
Non-
users
Possible interventions (PI)
High profit 
margins
Attract and finance 
organized crime groups, 
including terrorist activities
Increased risk of trafficking 
and corruption 
Money laundering activities
High level of violence, 
criminal motivation 
and risk-taking
X 
X 
X
X
X 
X
X
X
PI 25: Securing political commitment for 
evidence-based responses to confront 
trafficking, sales, and organized crime
PI 26: Strengthening international 
cooperation, including civil 
society organizations 
PI 27: Focusing law enforcement 
interventions on production, 
trafficking, and organized crime
PI 28: Introducing legal instruments against 
money laundering and asset seizures
High price 
levels
Drug users commit 
acquisitive crime to finance 
their drug consumption
X X PI 6, PI 10, PI 11, PI 12
PI 29: Improved means for rehabilitation 
of offending drug users
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Illegal drug trade leads to high profit 
margins
Illegal drug markets are attractive to criminals and 
organized crime groups because of the high profit 
margins and because the money is diverted outside 
legal financial flows. Both factors contribute to explain-
ing the observed links to other organized crime oper-
ations. The substantial amount of drug-related money 
passing in undetected flows around the world makes 
this black market of high interest to other organized 
crime networks, notably those engaged in money 
laundering, human trafficking, arms smuggling, and 
terrorism. Drug-related and non-drug-related crimes 
are connected in different ways. Terrorist groups see 
in the illegal drug market an opportunity to gain 
funding for their activities, causing, as one example of 
direct damage, strained international relations (161). 
Another example is when the profits generated in 
illegal drug markets encourage diversification into 
other illicit activities, and the networks and logistical 
infrastructure established for this purpose are utilized 
to also traffic other commodities (11).
The diversion of significant sums of money causes 
economic damage to financial systems and govern-
ment budgets alike. Corruption of public officials, from 
low-level law enforcement officers at one end of the 
spectrum to high-level members of the judiciary and 
politicians at the other end, is a systematic feature of 
all illicit markets.Drug markets have been identified 
to be one of the two most corruptive influences in 
Europe, with organized crime groups most commonly 
targeting low-ranking police and public administration 
employees (11). The aim of corrupting law enforce-
ment agents is normally to obtain information on 
investigations or operations, or to protect on-going 
illegal activities. Pressure from corrupt magistrates or 
prosecutors may, for example, obstruct police inves-
tigations of influential individuals who are members 
of criminal networks. The corruption of government 
officials at all levels, and most particularly in the sphere 
of law enforcement agencies, judicial institutions, and 
prison systems, is an important factor for ensuring the 
smooth operation of illegal markets. This, consequen-
tially, produces a corrosive effect on public institutions, 
undermining governmental authority (11). 
A significant proportion of money laundering activity 
is cash-based, low-tech, and labour intensive. The 
business sectors most targeted include gastronomy, 
the gambling and casino industry, retail trade, and 
especially the food, clothing, and transportation sec-
tors (162). This type of ‘low level’ money laundering 
accounts for approximately 20% of all laundered 
funds (163). The drug trade generates large sums of 
money that will eventually have to be transferred into 
legal financial markets. While it is difficult to estimate 
the extent of illicit financial flows, drug trafficking 
is assumed to be a major part of all illicit funds in 
Europe. Illicit drug trade was estimated to account 
for roughly 20% of all crime proceeds and about 50% 
of all transnational organized crime proceeds in 2009 
(160). It is estimated that illicit drug markets in the EU 
(heroin, cocaine, cannabis, amphetamines and ecstasy) 
account for one-quarter of the proceeds from all illicit 
retail markets (162). The EMCDDA assumes that about 
44% of retail profits are laundered from European drug 
markets and estimates that, based on that assumption, 
as much as EUR 11 billion arising from the drug retail 
trade in the EU might be laundered annually (11).
Violence may be seen as an inherent and systemic 
component of the illicit drug market and can be the 
result of different factors. First, it may be a result of 
the effects that drugs have on individual users, such 
as violence stemming from drug-induced psychosis, 
or as a part of an acquisitive crime, such as robbery. 
Further, the production and trafficking of illicit drugs 
are linked to violent crimes, including homicides (gang 
wars, etc.). Violence can be used to gain or maintain 
market shares or to resolve disputes (164;165). This 
is related to the lack of legitimate problem-solving 
mechanisms in illegal markets. Conflicts involving 
parties who are both involved in criminal acts are 
bound to be solved outside of the legal system, hence 
the increased probability of violent solutions. 
The influence of illegal drug trade on organized crime, 
terrorism, corruption, money laundering and mar-
ket-related violence all have substantial negative 
effects on society and individual members, including 
drug users. Drug users may be affected by organized 
crime, terrorism, and other illicit activities as much as 
other societal members, but in addition, they may 
be more directly affected through their drug-related 
activities. In a setting of corruption, for instance, cor-
rupted law enforcement officials may encourage drug 
users to buy their way out of criminal investigation 
through the payment of bribes.
Possible interventions (PI)
PI 25: Securing political commitment to confront traf-
ficking, sale and organized crime
To ensure the required human and economic resources 
to confront and reduce trafficking, sale and organized 
crime, political commitment is needed. The different 
forms and shapes of illegal drug markets require a 
coordinated multi-agency supply reduction approach. 
Applied measures and interventions should be evi-
dence-based. While supply reduction is a key drug 
policy area, there are large gaps in the existing knowl-
edge base (166). The on-going work by the EMCDDA 
on developing supply reduction indicators constitutes 
an important step towards more evidence-based and 
effective policies in this field (167). 
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PI 26: Strengthening international cooperation, including 
civil society organisations 
Collaborative action between civil society and public 
authorities leads to more dynamic, efficient, and effec-
tive development and implementation of drug policies 
and action plans. Particularly in drug policy, which 
influences such a wide range of fields of action and 
aspects of concern, crosscutting or network-based civil 
society actors can often overcome sectorial barriers 
much easier than actors in public administration can. 
Additionally, cooperating with civil society ensures 
that citizens are not alienated from the political pro-
cess, a concern of modern democracies. Input from 
civil society creates added value to the policy plan-
ning and implementation process, enhancing the 
legitimacy, quality, understanding, and longer-term 
applicability of policy initiatives. Civil society organiza-
tions provide a wide range of contributions for policy 
development and implementation (168). 
International networking between different stake-
holders and agencies at the professional level, such as 
the Pompidou Group’s Airports Group, International 
Network on Precursor Control, and South East Europe 
Cooperation, set examples of practical, enhanced, and 
flexible cooperation models. 
PI 27: Focus on law enforcement against drug production, 
trafficking and organized crime
In order to increase the effectiveness and efficiency of 
law enforcement, many governments are encouraged 
to focus their law enforcement activities on the produc-
tion of drug, trafficking, and organized crime structures 
(1). Greater cooperation, information, and intelligence 
exchange between specialized law enforcement teams, 
which focus on criminal groups trafficking these dif-
ferent types of drugs, should be facilitated to ensure 
the absence of gaps in the strategic analysis and con-
sequent law enforcement responses (11).
PI 28: Introducing legal instruments against money 
laundering and asset seizures 
The identification, disruption, and dismantling of seri-
ous organized crime groups involved in drug trafficking, 
money laundering, and corruption are key elements 
of law enforcement activities in Europe. Different legal 
instruments, such as tracking, freezing, seizing, and 
confiscating assets exist on both national and interna-
tional levels (169). Judicial cooperation in cross-border 
money laundering cases is paramount to making these 
instruments work effectively. Furthermore, it should be 
kept in mind that for money laundering to be effective, 
enablers working in the financial and legal sectors 
are needed. One of the key enabling factors in these 
sectors is negligence or incompetence in applying 
anti-money laundering measures (170). Authorities 
should be attentive to this and must ensure appropriate 
over-sight procedures and mechanisms.
Illegal drug trade leads to high price 
level
As mentioned in 3.2.2, economic compensations for 
the risk of severe legal responses facing those involved 
in drug manufacturing and trafficking have led to an 
elevated price level for illegal drugs. In addition to the 
health consequences already discussed, the high price 
level also makes it difficult for drug users, and problem 
drug users in particular, to support their habit by legal 
means only. Required funds are frequently obtained 
through various forms of acquisitive crime, prostitu-
tion and drug dealing, such as small-scale dealing 
as a means of obtaining drugs as payment-in-kind. 
Fraud, property crime, and robbery are commonly 
mentioned as income sources by drug users (80) 
and some studies suggest that robberies increase as 
a consequence of price hikes in illegal drug markets 
(171). These unlawful income-generating activities 
create substantial harms and costs to society at large 
(172) and have negative repercussions on the conduct 
and economic behavior of many drug users. They may 
also lead many users to circumstances in which they 
are more exposed to the risk of being coerced into 
sexual exploitation and trafficking (173). 
As intended, reduced availability and high price levels 
add to the complexity of obtaining drugs and are likely 
to reduce consumption. Users of drugs like heroin and 
amphetamine respond to price increases by reducing 
their consumption (174), but the addictive property 
of many substances may lessen this response to some 
extent. One result of the elevated price level, however, 
is that users spend a large share of their disposable 
income and time trying to obtain drugs and funds, 
while spending less on daily necessities such as food, 
clothing, housing, and other vital needs. 
Possible interventions (PI)
PI 6: Develop prevention strategies: raise awareness, 
provide relevant information, education and commu-
nication targeting relevant groups
PI 10: Increase capacities and upgrade current practices 
of low-threshold services to respond more effectively to 
drug users’ health and social needs,8 including interven-
tions tailored to NPS users 
PI 11: Encourage peer-to-peer work, and promote 
peer-training in outreach work, including measures to 
reduce drug-related deaths, early involvement of emer-
gency services, and measures to access and use first aid
PI 12: Ensure effective Naloxone distribution to medical 
and emergency services to prevent lethal overdosing
8. Including, but not limited to, scaling up Needle and Syringe 
Programs (NSP); Supervised drug consumption facilities 
(SDCF) Community-based outreach programs (CBO); Opioid 
maintenance therapy (OMT) and other drug treatments; 
Antiretroviral therapy (ART); Vaccination, diagnosis and 
treatment of viral hepatitis
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PI 29: Improved means for rehabilitation of offending 
drug users
In addition to various demand reduction PIs men-
tioned above, the adoption of measures such as 
treatment, education, and training, which can be 
used as alternatives to, or in addition to, conviction or 
punishment for drug-related offences, constitutes an 
important means for the rehabilitation of drug users 
who are in conflict with the law. It is also important 
for the avoidance of adverse and often long-term 
consequences that may result from a criminal con-
viction (see 3.5 below).
Effects resulting from stigmatization
Stigmatization, and subsequent responses such as 
discrimination and marginalization, may result from:
► Using illegal drugs/criminal behaviour
► Having a criminal record
► Having been imprisoned
► Having been apprehended publicly
The perception that drug users are ‘criminals’ can 
often lead to discriminatory behaviour towards them. 
There is an increasing concern among policymakers 
and people in general about stigmatization of drug 
dependence and subsequent discrimination of those 
dependent on drugs. Stigmatization of individuals 
dependent on drugs has been increasing in countries 
that have implemented austerity measures (175). The 
political and societal acceptance of dependence as 
a health condition, little different from other chronic 
diseases, appears to be severely undermined by the 
lack of knowledge and the existence of prejudice and 
stigmatization at all levels of society. Stigmatization 
may also affect recreational users of illegal drugs. 
Table 5 – Effects resulting from stigmatization 
Mechanisms Unintended Consequences Users
Non-
users
Possible interventions (PI)
Stigmatization 
due to 
perception 
of drug users 
as criminals
Low self-esteem and 
reduced motivation for 
drug users to engage 
in economic activity 
and social life 
Limited or reduced 
access to community 
life and services 
Potential exacerbation 
of already existing forms 
of discrimination 
Increased readiness to 
engage in low status 
or illegal activities 
Increased risk of arrest 
and pre-trial detention
X 
X 
X
X 
X
X 
X 
X
X 
X
PI 16
PI 30: Recognizing and implementing 
obligations under international 
and national legal instruments 
PI 31: Raising awareness on the 
consequences of not respecting 
the rights of drug users 
PI 32: Developing best practice 
manuals and anti-discrimination 
training for professionals 
PI 33: Setting performance indicators to 
prevent discrimination and stigmatization
PI 34: Offering employment opportunities 
and vocational training for drug users
Effects of stigmatization
A criminal label may lead drug users to self-identify 
as criminals (low self-esteem), and may also lead to 
others, such as employers, identifying users as crimi-
nals. Stigmatization stems from a process of internal 
and external identification, and may reduce both the 
opportunity and the motivation for participation in 
social life. For instance, socially-visible exposure to 
enforcement action, such as an apprehension, has the 
potential to harm a user’s reputation and self-esteem, 
leading to reduced motivation for achievement and 
participation in social life.  
An interdependent relationship exists between drug 
dependence and unemployment and poverty. The 
stigma associated with drug use and its criminalization 
can reduce a person’s employment prospects by reduc-
ing productivity and the chance of finding work. In 
turn, unemployment can cause stress and anxiety, 
financial difficulties, dissatisfaction and disaffection, 
all of which are risk factors for initiation, perpetuation, 
intensification, or resumption of drug use (176). This 
has been described as a process of “cumulative disad-
vantage” (177). Furthermore, discriminatory practices 
put in place by employers, which may be related to 
criminal records or social stigma as drug users, often 
reduce the chances of finding regular employment 
or in some cases make it impossible, particularly in 
times of high general unemployment. Many drug users 
are well aware of this stigmatization as their limited 
skills, poor or non-existent qualifications, and gaps 
in their work history may make finding employment 
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extremely difficult. This often leads to the conclusion 
that seeking employment is utterly pointless (178), 
and as a consequence, there is a high risk that the 
role of social outcast will be deliberately assumed. 
This may lead to users associating themselves with 
the world of criminals and criminal activity as a source 
of identification, belonging, and as a way of finding 
other opportunities to sustain a living.
The stigmatization and subsequent marginalization 
of individuals who regularly use drugs also has a 
negative impact on social relationships. Stigma and 
social exclusion can lead to the loss of human capital, 
as people who use drugs are unable to contribute 
to or participate in society and community (179). 
Drug use and its criminalization may drive users to 
the margins of society and create distance between 
them and their communities and families. Drug users 
who are criminalized may experience a weakening of 
social bonds to conventional society (180). This social 
maladjustment may, in turn, lead to recidivism and 
further drug use. Further, marginalization can con-
tribute to drug use, just as drug use can contribute 
to the marginalization of some users. Indeed, drug 
use can cause deterioration in living conditions, while 
processes of social marginalization can be a reason for 
initiating drug use (181). Several risk factors for mar-
ginalization can be attributed to drug use, including 
unemployment, homelessness, reduced access to care 
services, incarceration, and sex work (181). 
It is commonly acknowledged that drug users from 
certain ethnic groups or minorities may experience 
a double stigma. This is due to the prevalence of 
popular images that characterize visible minorities as 
habitual drug users, especially because many illegal 
drugs come from outside Europe. As the UNODC 
states, in the case of substance abuse, people often 
conveniently blame “foreigners,” “outsiders” or generic 
“others” for the spread of drugs and associated social 
problems (182). Existing data show, however, that 
there is little evidence for such perceptions to hold 
true. Information on drug use, patterns, and conse-
quences within minorities remains scarce. Fear of 
stigmatization makes the collection and dissemination 
of data difficult. Thus, comparisons with the general 
population on levels of drug use are rarely possible. 
Existing practices in criminal investigations, law 
enforcement, and criminal procedures vary across 
Europe, depending on existing laws and regulations, 
as well as on their interpretation. There are noticeable 
differences in regard to the risk of arrest and pre-trial 
detention of suspected drug users, dealers, and traf-
fickers. Still, there appears to be a general tendency 
that people who are suspected of drug use or who 
are known users face a higher risk of arrest or pre-trial 
detention. This in turn leads to a higher risk of exposure 
to the adverse consequences of arrests and pre-trial 
detention, including stigmatization, possible loss of 
employment or housing, and strain on social relations. 
These consequences affect both the drug users and 
their familial and social circles equally adversely. 
Possible interventions (PI)
PI 30: Recognising obligations under international and 
national legal instruments 
In this context, it is important to remember that gov-
ernments have an obligation under international 
and national legal instruments to safeguard the fun-
damental standards of human rights and the rule of 
law, which also apply to drug users. As mentioned 
in chapter 1, these obligations are described by the 
Council of Europe (CoE) Convention for the Protection 
of Human Rights and Fundamental Freedoms and UN 
documents (8) and guarantees:
► The right to life
► The right to protection of health
► The right to non-discrimination 
► The prohibition of inhuman or degrading 
treatment 
PI 31: Raising awareness on the consequences of not 
respecting the rights of drug users
The consequences of not respecting the human, legal 
and social rights of drug users are diverse and com-
prehensive. Increased public attention and improved 
knowledge are needed to increase awareness by rel-
evant stakeholders. Regular collection of appropriate 
data and sound analyses will help policy makers to 
take action. 
One example is the collection of ethnicity and cul-
ture-related data. This may be a beneficial instrument 
for shaping drug policy interventions for specific target 
groups and may lead to an adoption of culturally-sen-
sitive drug strategies. Such data can provide baseline 
information on the situation of minority groups, which 
will then form the basis for action and later help in 
evaluating the effectiveness of outcomes. Collecting 
relevant data does not need to be stigmatizing, but 
can help to avoid prejudice and discrimination. It also 
serves to assess the effectiveness of policies, so that any 
necessary changes and adjustments may be made (183).
PI 32: Developing best practice manuals and anti-dis-
crimination training for professionals 
European non-discrimination law, as codified by the 
EU non-discrimination directives and Article 14 and 
Protocol 12 of the European Convention on Human 
Rights, prohibits discrimination across a range of con-
texts and grounds. European non-discrimination law 
stems from these two sources as complementary sys-
tems, drawing on them interchangeably to the extent 
that they overlap, while highlighting differences where 
they exist. A handbook, provided by the Council of 
Europe with an extensive body of case law developed 
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by the European Court of Human Rights and the Court 
of Justice of the European Union in the field of non-dis-
crimination, provides a highly useful and accessible 
starting point for developing national anti-discrimina-
tion manuals. The material contained in the handbook 
is intended to serve professionals, including judges, 
prosecutors and lawyers, as well as law-enforcement 
officers, and policy makers alike in the EU and Council 
of Europe Member States and beyond (184).
PI 33: Setting performance indicators for preventing 
discrimination and stigmatization
To ensure the effective implementation of antidiscrim-
ination policy and strategy, performance indicators 
are an important and useful tool. These should be 
developed on different levels, including indicators 
on existing types and levels of discrimination of drug 
users, indicators of institutional and structural dis-
crimination, and indicators on professional practices 
and perceptions (185). Audits on the basis of these 
indicators should be carried out within all relevant 
institutions and services (186). In practice, this would 
include law enforcement agencies, social and health 
services, as well as other institutions coming in contact 
with drug users, such as housing and employment 
agencies and welfare offices. 
PI 34: Offering vocational training and employment 
opportunities for drug users 
The relationship between drug use and employment 
status is complex and characterized by reciprocal 
causality: drug use exacerbates the risk of unem-
ployment, while unemployment may increase the 
risk of drug use. To break this cycle, different steps 
are necessary. First, the personal, health, lifestyle and 
other problems of drug users must be identified and 
addressed before they are ready for vocational train-
ing, work rehabilitation, and retaining paid employ-
ment (187). Following this, adequate educational offers 
are needed to improve poor educational records, and 
subsequently, professional training and qualification 
courses should be offered together with supported 
or assisted employment possibilities. This process 
should be accompanied by measures such as debt 
counseling and participation in self-help groups to 
support the individual stabilization process.
Effects of criminal records and 
imprisonment for drug offences
While the intended consequences of a criminal record 
remain valid in all respects, the unintended effects may 
reduce many social life opportunities and may have 
a significant effect on users’ interpersonal relations. 
These consequences may include the alienation of 
family and friends and limitations in available social 
support. Further, the imprisonment of drug using 
offenders has significant unintended consequences, 
which may have major effects on the lives of and the 
rehabilitation opportunities for drug users.
Table 6 – Effects of criminal records and imprisonment for drug offences
Mechanisms Unintended Consequences Users
Non-
users
Possible interventions (PI)
Limit 
opportunities 
due to criminal 
records
Reduced employability
Limited access to housing
Limited educational 
opportunities 
Restricted mobility due to 
travel restrictions and loss 
of driver licence
Increased risk of stigmatiza-
tion and social exclusion
Increased risk of being 
subject to police surveillance 
and investigations
X
X
X 
X 
X
X
X
X
X
X
PI 29, PI 34
PI 35: Restricting the content of criminal 
records provided for the purpose 
of employment, housing, etc.
PI 36: Inter-agency coordination and 
cooperation between law enforcement, 
health and social services
PI 37: Training prison staff and probation 
officers to assist drug users on probation 
in acquiring training opportunities, 
employment and housing
Social 
confinement 
and shattered 
ties with the 
community 
due to 
imprisonment
Shattered ties with 
individual social 
support networks
Increased risk of 
reoffending and relapse 
Exposure to violence 
and health risks related 
to prison subculture
X
X
X X
PI 23, PI 24, PI 29, PI 34, PI 35
PI 38: Provide for drug fee wards and 
therapeutic communities in prisons
PI 39: Strengthen links between prison 
authorities and local authorities
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Limit opportunities due to criminal 
records
When caught by law enforcement officers, offences 
such as drug trafficking, dealing or drug production 
usually result in a criminal record for the offender. 
In several countries, however, this may also occur if 
a problem drug user or a recreational user is being 
apprehended for drug use/possession. For youths in 
particular, who may be using drugs because they are 
risk-seeking, oppositional, and/or vulnerable, the neg-
ative effects of a criminal record can be substantial and 
long-lasting. For all drug offenders, however, having 
a criminal record for drug-related offences may have 
several severe but unintended effects.
Criminal records, especially when containing drug-re-
lated offences, are frequently an obstacle to obtain-
ing employment. For many professions or types of 
work places, a drug-related offence is an exclusion 
criterion for employment. This comes in addition to 
the negative effects of stigmatization resulting from 
drug criminalisation. Further, when seeking to rent a 
place to live, a criminal record may also be an obstacle. 
For many landlords, the existence of a conviction for 
a drug-related offence constitutes a sole and single 
ground to refuse tenancy. Thus, the housing market 
has increasingly become a problem for drug users and 
an obstacle for re-integration of problem drug users. 
Furthermore, criminal records can also influence on 
educational opportunities. Some educational insti-
tutions require the presentation of a criminal record, 
and drug-related offences constitute an exclusion 
criterion. In some countries, courses leading to degrees 
in medical or pharmaceutical studies exclude people 
with a criminal record on drug-related offences from 
entering studies or receiving licences for practice.
Visa-regimes and entry requirements in several 
countries exclude people with prior convictions for 
drug use from entering, be it for private, educational, 
professional or other purposes. Further, recorded 
convictions for drug-related offences often lead to 
the stigma of being addicted and a criminal, with 
the entailing consequences of marginalization and 
exclusion from mainstream social and community 
life. This in turn can lead to reduced accessibility of 
social and health services (see 3.2 above). Furthermore, 
people with prior drug use convictions run the risk 
of increased police surveillance and of becoming 
suspects in investigations. 
Possible interventions (PI)
PI 29: Alternative sentencing options
PI 34: Offering vocational training and employment 
opportunities for drug users
PI 35: Restrictions of content of criminal records provided 
for public purposes 
To mitigate the adverse effects of criminal records, 
legislation can include statutes of limitations (188):
► Certain types of (minor) drug offences can be 
removed from the criminal record after a certain 
period of time. 
► Warnings, community service orders, and treat-
ment orders can be exempted from inclusion 
on criminal records.
► The content provided from the criminal record 
for public use (for the purpose of obtaining 
housing, employment, etc.) can be restricted 
and exclude minor (drug-related) offences.
► Infringement of administrative laws can be 
excluded in the criminal record that is provided 
for public use.
PI 36: Inter-agency coordination and cooperation 
In order to ensure that interventions aimed at coun-
teracting the unintended consequences of criminal 
records are implemented effectively, it is important 
that all involved stakeholders and agencies be com-
mitted. If this is not achieved, different institutional 
cultures and perspectives run the risk of cancelling out 
anticipated effects. In this respect, joint training on the 
awareness and the application of different alternative 
options, such as those listed above, can help to ensure 
institutional mainstreaming and the coherent pursuit 
of goals. Organizing joint training activities for law 
enforcement, judiciary, and social and health services 
is likely to be an effective means to build cooperation 
in the achievement of cross-sectorial policy coherence. 
PI 37: Training prison staff and probation officers 
Prison staff and probation officers who assist in acquir-
ing training opportunities, employment, and housing, 
play a key role in the reintegration of offenders and 
specific efforts need to be undertaken in order to pro-
vide assistance. Employment and housing are crucial 
factors for a successful reintegration of offenders into 
society, as lack of adequate housing and employ-
ment are frequent causes of relapse into drug use 
and criminal recidivism. From this perspective, the 
training of prison staff and probation officers is of 
particular priority. 
Social confinement and shattered ties 
with the community due to imprisonment
Drug users make up a significant part of the overall 
prison population, many of whom have used illicit 
drugs at some point, and many of whom have chronic 
drug use problems. Because of the illegality of the 
drug market and the high cost of drug use, often 
funded by criminal activity, more problematic forms 
of drug use are accompanied by an increased risk of 
imprisonment (189).
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The process of arrests and imprisonment and the 
attitude towards users during imprisonment may 
increase the risk of violence and of other acts specific 
to prison subculture. Negative effects of imprison-
ment are aggravated by potential continued criminal 
involvement as a result of drug addiction and daily 
exposure to criminal networks in the prison setting. 
Being an inmate, especially one sentenced for a drug 
offence, increases the risk of severe social stigma and 
discrimination. This creates a situation that may result 
in significant difficulties for social reintegration and 
financial independence after completion of sentence 
and return to the community. Often times, negative 
effects of imprisonment also reflect on the families 
and close relatives of prisoners. 
As a consequence of shattered ties with familial and 
social networks during the period of incarceration, 
prisoners are exposed to a range of physical, practical, 
and psycho-social challenges following their release 
from prison and during return to their communities. 
These challenges include potential social isolation 
and lack of finding employment and housing, among 
others. These challenges increase the risk of relapse 
and/or drug use, as well as engagement in crimi-
nal activity. Another consequence is a significantly 
increased mortality risk among those who revert back 
to street drug use (190). 
Possible interventions (PI)
PI 23: Provide relevant treatment and rehabilitation 
services in prisons, detention and facilities for refugees 
and immigrants
PI 24: Facilitate adequate vaccination programs and 
prophylactic measures to drug users and their associates
PI 29: Alternative sentencing options
PI 34: Offering vocational training and employment 
opportunities for drug users
PI 35: Restrictions of content of criminal records provided 
for public purposes
PI 38: Provide for drug-free wards and therapeutic com-
munities in prisons
Drug-free wards and therapeutic communities have 
proven to be an effective means of reducing exposure 
to the criminal prison subculture into which drug 
using inmates are frequently drawn (191). Prison can 
present an opportunity to enter treatment and the 
prison setting allows for the creation of therapeutic 
communities and drug-free wards. A number of pilot 
projects have shown the success of this approach, 
which on one hand refers drug-using inmates to ther-
apy and treatment, and on the other hand provides 
thorough care for those who were in therapy prior to 
incarceration (191). 
PI 39: Strengthen links between prison authorities and 
local authorities
Cooperation and communication links between health 
prison services and those outside the prisons need 
to be improved. Regular meetings on the regional 
or community level and joint training of medical 
staff from both prison healthcare and public health 
services can be a very effective means in this respect.
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Chapter 4 
Discussion
Although it is acknowledged that drug control policy 
is an important element of an integrated and bal-
anced approach to counter illegal drug problems, 
control costs and unintended consequences are 
still frequently referred to as arguments for a pol-
icy change. In particular, enforcement against drug 
users is increasingly being debated as it is accused of 
violating essential principles of democratic societies, 
such as human rights. Drug prohibition itself is being 
questioned, and the recent legalization of cannabis 
supply and recreational use in some US states reflects 
this opposition. Further, how governments allocate 
their resources is always a topic of dispute, particularly 
in times of austerity. Thus, public expenditure on drug 
control policy interventions is under scrutiny, both 
by those wanting to change current drug policy and 
by those concerned that scarce resources are not 
optimally spent. This report has examined costs and 
unintended consequences of drug control policy. 
Improving and employing 
public expenditure estimates 
for drug control policies 
Improved knowledge of public expenditure on drug 
control policies is useful and wanted. Public expendi-
ture estimates calculate the amount of resources spent, 
or required, to implement targeted interventions 
and can reveal to what extent policy intentions are 
reflected relevant budgets. Still, many governments 
do not provide a full summary of resources expended 
on drug policy in general and on control policy in 
particular. Wide-spread lack of thorough knowledge 
seriously hampers sound planning and evaluation 
needed to improve the design and implementation 
of cost-effective interventions to reach stated policy 
goals. Systematic evaluations are needed to find out 
what is effective, what the optimal means are for 
reducing drug-related problems and which interven-
tions produce the best value for money. Estimates of 
drug-related public expenditure are an indispensable 
part of such a policy evaluation. Regardless of whether 
one wants to conduct a cost-benefit analysis or a 
cost-effectiveness analysis, reliable and valid estimates 
of public resources consumed by policies are required. 
Chapter 2 stresses the importance of obtaining such 
estimates and urges a standardization of definitions 
and methods to make estimates comparable across 
time, policy areas and countries. Policymakers need 
to fully acknowledge the importance of cost studies 
as a tool for scientifically-based decisions and give 
them higher priority. 
To improve public expenditure estimates, there are 
some crucial issues that must be addressed. First, 
one has to arrive on a common understanding of 
the scope of exercise. Is it meant to reflect all public 
expenses on drug-related crime or just the public 
spending on drug law enforcement? For example, it 
has been discussed whether the costs of countering 
crimes committed under the influence of drugs should 
be included in the estimates of public expenditure 
of control policy. The chosen response to this and 
similar questions has substantial impact on the size 
of the estimate and on its interpretation. So far, there 
has been no commonly-agreed definition of what to 
include in public expenditure estimates in this field.
Second, relevant data needs to be improved and made 
known and available to analysts. A comprehensive 
inventory of national and international expenditure 
data sets would be a useful start, including a sys-
tematic compilation of international data sets with 
harmonized definitions and comparable data. The 
appendices of this report and the accompanying 
web site (http://www.emcdda.europa.eu/topics/drug-
related-public-expenditure), can be seen as a first 
systematic contribution towards this end. 
Third, although some useful data sources exist, much 
of the required cost information is not readily avail-
able. For example, money spent on drug control is 
often not labelled as such in public budgets and 
accounts. When expenditure data are embedded 
in broader or more general budgets, for example, 
funds encompassing more comprehensive health or 
security goals, a common agreement on assumptions 
and types of models applied is required in order to 
extract the fraction of funds attributable to drugs. 
Chapter 2 presented two alternative methodological 
approaches for estimating public expenditure in these 
cases: the top-down and the bottom-up approach. 
To illustrate how these methods have been applied, 
Chapter 2 further offered examples of empirical studies 
of individual drug control sectors (public expenditures 
for police, court systems, and customs and prisons) 
and of national estimates of total expenditure on 
drug control policy. The examples clearly indicated 
that even within each of the two methodological 
approaches, large differences exist in how the same 
types of expenditure are estimated and what types 
of expenditure are included in studies. Therefore, the 
development of guidelines to improve data collection 
systems and to develop economic models to estimate 
costs is highly desirable.
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The aforementioned empirical analyses showed some 
interesting and useful conclusions. Public expenditure 
on drug-related control policies represents 40% to 
70% of the total funds spent on drug policy in Europe, 
depending on the country. Taking into account that 
resources for all elements of drug policy (prevention, 
law enforcement, treatment and harm reduction initia-
tives) amounted to an interval of 0.01% to 0.5% of gross 
domestic product (GDP) of these countries, one may 
conclude that the volume of resources consumed for 
control policy is significant. However, to further increase 
knowledge and obtain more precise estimates, more 
and better data and modelling techniques are required.
Acknowledged and taking into 
account unintended consequences 
The unintended consequences discussed in Chapter 
3 are of policy value for two reasons. First, they should 
be taken into account when policy decisions are made. 
Second, these unintended but predictable negative 
effects should be ameliorated where possible (20). 
In order to accomplish the latter, it is important to 
identify the both sources of those consequences, as 
well as who is affected. In addition to discussing a 
range of health and non-health effects of unintended 
consequences, this report has identified their bearers 
and lists almost 40 possible interventions that may 
reduce negative effects.
The unintended consequences of drug prohibition 
have led to substantial human suffering and have 
absorbed large amounts of human and economic 
resources that might have been allocated to other 
policy goals. The unmet need of pain relief and pal-
liative care due to the strict enforcement of the UN 
conventions is perhaps one of the most serious con-
sequences for non-users of illegal drugs. The World 
Health Organization illustrates the wide-ranging scope 
of the problem by estimating that 5.5 billion people 
have seriously reduced, or total lack of, access to 
essential medicines, and suggests that this may in part 
be due to governments’ strict implementation of the 
UN conventions (44). Additionally, the fact that many 
opioid dependent users are denied access to the most 
effective treatment – opioid substitution treatment 
(OST) – is of critical importance for the affected drug 
users and their relatives. 
Further, illegal markets have consequences for individ-
uals and society, including participants’ involvement 
in other types of criminal activities and in terrorism, 
its impacts on legitimate businesses and the wider 
economy, its strain on and corruption of government 
institutions, and its impacts on wider society (11). 
Figure 4.1 illustrates these consequences:
Figure 4.1 – The widespread ramification of illicit drug markets
Source: EMCDDA/Europol (11).
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As discussed in Chapter 3, the prohibition of drug 
manufacturing and sale have induced large profit 
margins at each level of the distribution chain. It 
is estimated that the illegal EU retail drug market 
was worth at least EUR 24 billion (range EUR 21 to 
31 billion) in 2013, with the cannabis market being 
the largest (35%), followed by the heroin (28%) and 
cocaine (24%) markets (11). These risky but large rev-
enues have attracted criminals and organized crime 
groups to the drug economy. 
In addition to law enforcement activity geared towards 
disrupting illicit drug supply, most European countries 
also enforce some sort of sanctions against users, 
with the intended effects of deterring drug use and 
preventing normalisation and spread of use. The drug 
conventions oblige states to ensure that possession of 
drugs, even in small quantities, shall be a punishable 
offence. They offer, however, alternatives to convic-
tion or punishment, including treatment, education, 
aftercare, rehabilitation and social reintegration (4). 
Great variation exists in how strictly countries apply 
drug laws and to which substances. Although some 
countries are known for extreme enforcement, many 
countries have decriminalized drug use and possession, 
and very few imprison offenders for drug use alone. 
Still, drug control policy and human rights are very 
often linked. The obligations of States under the 
Council of Europe and United Nations Conventions 
are to protect fundamental rights and freedoms, in 
particular the right to life and human dignity, the right 
to protection of health, the right to equitable access 
to quality health care services for all, the prohibition 
of any type of discrimination (8), as well as the right 
of children to be protected from narcotic drugs and 
psychoactive substances. Still, as discussed in Chapter 
3, state enforcement of criminal drug laws has in 
some cases resulted, directly or indirectly, in serious 
and sometimes widespread and systematic human 
rights violations. When poorly developed and imple-
mented, drug policies have led to police harassment 
and violence, arbitrary detention, disproportionate 
sentencing and incarceration, discrimination, viola-
tions of the right to health, and other ill-treatment. 
These unintended consequences of control policy 
are likely to vary greatly, depending on the drug and 
the operational context. Unintended consequences 
to drug uses are also likely to vary according to age, 
gender, race and socioeconomic factors, dispropor-
tionately affecting already disadvantaged groups. 
Examples of human rights violations have fuelled 
the call for liberalisation and humanisation of drug 
control polices.
Drug control is not simply a choice between total prohi-
bition and full legalisation. It is a choice among options 
on a continuum between these two extremes. The 
principle of proportionate response to drug crimes has 
increasingly gained support and is evident in import-
ant policy documents, such as the UN’s “Report of the 
International Narcotics Control Board for 2016” (4). As 
recently illustrated in “Penalties for drug law offences 
in Europe at a glance” (5), the UN conventions are 
enforced very differently across Europe. In all European 
countries, however, alternatives to coercive sanctions 
have been repeatedly suggested and encouraged by 
many stakeholders. The most recent is perhaps the 
EU’s action plan on drugs 2017-2020, which explicitly 
calls for the use of alternative sanctions for drug-us-
ing offenders (192). Two topical reports, “Alternatives 
to punishment for drug-using offenders” (193) and 
“Study on alternatives to coercive sanctions as response 
to drug law offences and drug-related crimes” (194), 
examine possible changes within the intent of the UN 
conventions. Proportionate responses and increased 
use of alternative sanctions are likely to ensure legit-
imacy and continued support for the control policy. 
Conclusion
The cost and unintended consequences of drug 
control policy will remain topics of controversy and 
debate. This report has highlighted the need for better 
estimates of public expenditure, as this can improve 
planning and evaluation of drug policy. This report 
has also listed a range of unintended consequences, 
their mechanisms and bearers, and offered an exten-
sive list of possible interventions to ameliorate their 
negative effects. It is important to note, however, that 
there is no public consensus on which unintended 
consequences matter the most; different weights may 
be assigned to the same consequence. Nor is there 
consensus on what measures governments should be 
permitted to take in managing those harms. Still, the 
increased acknowledgement and focus on the many 
and extensive unintended consequences of drug 
control policy has fuelled public response. To retain 
political support and legitimacy, locally adjusted inter-
ventions to ameliorate the negative and unintended 
effects should be implemented. 
We hope this report will contribute to improved public 
expenditure estimations and understanding of their 
importance. Further, we hope that unintended con-
sequences will be taken more fully into account when 
drug control policy is planned and implemented and 
that possible interventions are employed more often 
to reduce their negative effects. 
Page 48 ► Costs and unintended consequences of drug control policies
 ► Page 49
Appendix 1 – Available databases 
and potential indicators for drug-
related public expenditures 
Examples of international databases, which can be used for estimating drug-related 
public expenditures
Level of 
estimation
Examples of databases Estimation data
International EMCDDA Statistical 
bulletin
and 
Public expenditure 
database
– The EMCDDA statistical bulletin covers a broad range of 
areas including the most recent estimates of drug-related 
crime in the form of drug seizures, types of offence, price, 
purity and use in prison, and country responses to the 
drug situation in Europe. http://www.emcdda.europa.eu/
data/stats2015
– The EMCDDA also publishes the most recent national data 
on drug-related public expenditures available in Europe. 
– http://www.emcdda.europa.eu/topics/
drug-related-public-expenditure
WHO Database – Global Information System on Resources for the 
Prevention and Treatment of Substance Use Disorders 
(includes information about: prevalence and burden of 
Disease, monitoring and surveillance; policy; treatment 
system and services; pharmacological treatment; preven-
tion programmes for substance use and related harm; and 
human resources and civil society involvement).
Eurostat Public expenditure according to the Classification of the 
Functions of Government (COFOG)
COFOG published data according to two levels of classification 
(United Nations, 2008). The first classifies expenditure into 10 
general functions, one of which is “Public order and safety”. The 
second classifies expenditure into 69 groups, in which there 
are three indicators of interest: police service, law courts and 
prisons. The definitions below are provided by the UNODC.
From the Public order and safety section:
Police services
– Administration of police affairs and services, including alien 
registration, issuing work and travel documents to immi-
grants, maintenance of arrest records and statistics related to 
police work, road traffic regulation and control, prevention 
of smuggling and control of offshore and ocean fishing.
– Operation of regular and auxiliary police forces, of port, 
border and coast guards, and of other special police forces 
maintained by public authorities; operation of police labora-
tories; operation or support of police training programmes.
Page 50 ► Costs and unintended consequences of drug control policies
Level of 
estimation
Examples of databases Estimation data
Law Courts
– Administration, operation or support of civil and criminal 
law courts and the judicial system, including enforcement 
of fines and legal settlements imposed by the courts and 
operation of parole and probation systems.
– Legal representation and advice on behalf of the govern-
ment or on behalf of others provided by government, in 
cash or in services.
Prisons
– Administration, operation or support of prisons and other 
places for the detention or rehabilitation of criminals such 
as prison farms, workhouses, reformatories, asylums for the 
criminally insane, etc.
UN-CTS (Crime and 
Criminal Justice 
Statistics)
Data produced by UNODC have multiple sources. Mem-
ber States regularly submit to UNODC statistics on drugs 
(through the Annual Report Questionnaire) and crime and 
criminal justice (through the annual Surveys on Crime Trends 
and Operations of Criminal Justice Systems). Other data are 
collected through national surveys implemented by UNODC 
in co-operation with national governments or are compiled 
from scientific literature. UNODC attempts to maximise the 
comparability of the data and estimate regional and global 
statistics.
SPACE SPACE unites two related projects: SPACE I provides data 
on penal institutions and the population held in custody, 
as well as on certain conditions of detention, while SPACE 
II collects information on persons serving non-custodial 
sanctions and alternative measures.
Data are collected every two years by means of two question-
naires sent to the equivalents of the ministries of justice, the 
penitentiary administrations and the probation authorities of 
each country in Europe. The collection and validation of these 
data then takes place at the University of Lausanne, where 
analyses and interpretations for both projects are formulated 
through a common methodology. This methodology aims 
to allow comparisons among states at European level, by 
proposing SPACE categories instead of each country’s own 
national categories, while still including questions regarding 
the particularities of their specific sanctions and measures. The 
SPACE project produces two annual reports: SPACE I – Prison 
Populations and SPACE II – Persons Serving Non-Custodial 
Sanctions and Measures, presenting the data collected and 
the key points of the results.
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Level of 
estimation
Examples of databases Estimation data
European Sourcebook 
on Crime and Criminal 
Justice Statistics
The Sourcebook contains data from 41 European countries 
regarding their criminal justice systems. The book is structured 
into six main chapters covering different stages of the judicial 
system: Police Statistics, Prosecution Statistics, Conviction 
Statistics, Prison Statistics, Probation Statistics and, for the 2014 
edition, a final chapter on National Victimization Surveys. The 
data provided are systematically accompanied by texts and 
notes relating to the specificity of each country and which 
discuss the different challenges attributed to the comparison 
of the data.
Social Expenditure 
Database
The OECD Social Expenditure Database (SOCX) provides a 
unique tool for monitoring trends in aggregate social expendi-
ture and analysing changes in its composition. The main social 
policy areas are as follows: old age, survivors, incapacity-related 
benefits, health, family, active labour market programmes, 
unemployment, housing, and other social policy areas.
ESPAD Drug abuse prevalence among teenagers in European 
countries.
National Database of national 
statistics
Expenditures of different groups, in which can be found some 
indicators of interest: police service, law courts, prisons, medi-
cal and social services. 
Annual report from 
Social Services 
Department
Data on Social Services Department expenditures at regional 
level and the number of drug users receiving social benefits 
in connection with drug use.
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Appendix 2 – The international 
Classification of the Functions 
of Government (COFOG)
T
he COFOG classification has three structural 
levels. At the first level, government expenditure 
is broken down into 10 functions. These are then 
divided into 69 groups (second level of COFOG), which 
are themselves divided into classes at the third level – 
the most detailed classification level. COFOG permits 
an examination over time of trends in government 
outlays on particular functions (12).
The detailed three-level structure of COFOG includes 
financial flows of public finance, which are going from 
state and local (regional and municipal) budgets to 
non-profit organisations (NPOs) with drug-policy 
programmes. COFOG is a functional classification 
system used by the System of National Accounts 
1993. COFOG is a useful international classification 
system for spatial comparison (between countries) 
and also for time comparison (over time). In principle, 
its units of classification are individual transactions. 
This means that each outlay (purchase or transfer) 
should be assigned a COFOG code according to the 
function that the transaction serves. This principle is 
valid for both capital transfers (investment) and current 
(non-investment) transfers. Eurostat has published 
annual data according to the COFOG definitions for 
the European Union countries since the early 2000s.
The extensive structure of COFOG contrasts with the 
four-category division introduced by Reuter (20), 
based on the likely effects of services provided by 
drug policy programmes (namely prevention, treat-
ment, enforcement and harm reduction). Reuter’s 
programme division is the classification of the recip-
ients (NPOs) with drug-policy programmes. 
An example of an overview of public expenditure 
groups, broken down according to the main public 
functions pursuant to the international classification 
of the functions of the government at the third level, 
is shown in the table below.
A pragmatic approach towards drug-related research 
and public expenditure estimates would suggest 
adopting a classification such as COFOG, as proposed 
by Eurostat. The COFOG classification system guar-
antees annually available data for most European 
countries, according to harmonised definitions and 
standard data collection procedures. 
Public expenditures according to the classification of public functions
Public functions Public functions at the third level of classification
01 General public services 014 Basic research
03 Public order and safety 031 Police services
033 Law courts
034 Prisons
07 Health 071 Medical products, appliances and equipment
072 Outpatient services
073 Hospital services
074 Public health services
075 R&D health
09 Education 091 Pre-primary and primary education
092 Secondary education
094 Tertiary education
095 Education non-definable by level
096 Subsidiary services to education
10 Social protection 105 Unemployment
106 Housing 
107 Social exclusion 
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Appendix 3 – Summary tables: 
data from international databases
Table 1 – Public expenditure
Data and 
Statistics
Dataset Type of 
information
DATABASE YEARS Number of 
observations(*) 
Public 
expenditure
Expenditure 
of the 
general 
government
Law Courts Eurostat, 
European 
Union 
(EU)
1995-2015
Europe (31) = 473/651
Police Services Europe (31) = 473/651
Prisons Europe (31) = 473/651
Drug-
related 
public 
expenditure
Public 
expenditure 
on supply 
reduction
Total drug-
related public 
expenditure
Country Drug 
Profiles,
EMCDDA, (EU)
Last year 
available
EU (30) =20/30
Percentage 
spent on supply 
reduction
Percentage spent 
on demand 
reduction
(*) The number of observations reports the number of data records, taking into account the territory; countries and years available. 
The ratio compares the number of effectively reported observations with the total number of records, if no data were missing. 
Example: Europe (44) = 28/368: in Table 4, the conviction statistics of the European Sourcebook of crime and criminal justice sta-
tistics reports 28 data records, for the community sanctions imposed to drug offences in 2010, compared to the 368 data records 
that would exist if no data were missing, in the region Europe (which accounts with 44 countries). 
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Table 2 – Drug law offences
Data and 
Statistics
Dataset Type of information DATABASE Years
Number of 
observations(*)
Drug law 
offences
Drug Law 
Offences
Number 
of 
offences
Offences
EMCCDA
(EU)
1995-2014
EU (30) = 364/600
Offender EU (30) = 262/600
Offences 
by Types
Use
2004-2013
EU (30) = 230/300
Supply EU (30) = 238/300
Offences 
by drug
Cannabis
Total 2004-2013 EU (30) = 203/300
Use
2005-2013
EU (30) = 163/270
Supply EU (30) = 160/270
Heroin
Total 2004-2013 EU (30) = 186/300
Use
2005-2013
EU (30) = 159/270
Supply EU (30) = 160/270
Cocaine
Total 2004-2013 EU (30) = 185/300
Use
2005-2013
EU (30) = 159/270
Supply EU (30) = 176/270
Crack
Total
2005-2013
EU (30) = 50/270
Use EU (30) = 47/270
Supply EU (30) = 37/270
Amphetamine
Total
2005-2013
EU (30) = 163/270
Use EU (30) = 74/270
Supply EU (30) = 87/270
Methamphetamine
Total
2005-2013
EU (30) = 98/270
Use EU (30) = 74/270
Supply EU (30) = 87/270
Ecstasy 
Total
2005-2013
EU (30) = 162/270
Use EU (30) = 144/270
Supply EU (30) = 153/270
LSD
Total
2005-2013
EU (30) = 127/270
Use EU (30) = 108/270
Supply EU (30) = 95/270
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Table 3 – Prison population
Data and 
Statistics
Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Prison 
population
Persons held in 
institutions for drug 
users offenders 
outside penal 
institutions
Availability of 
institutions for drug 
users offenders, 
outside penal 
institutions
Space I, 
Council of 
Europe (CoE)
2014 CoE (47) =28/53
Situation of prison 
population
Population on 
1st January 
2009 & 
2014
2009: CoE (47) = 343/424
2014: COE (47) = 255/265
Total number of 
prisoners (including 
pre-trial detainees)
Total number of 
detainees held in 
remand institutions/
sections (pre-trials)
Total number of 
prisoners held in 
institutions serving 
a sentence
Total capacity of 
penal institutions
Surface area per 
prisoner (m^2) 
Evolution of prison 
population
Total number 
of prisoners 2000-2014
CoE (47) = 707/795
Prison population CoE (47) = 683/795
Legal status of 
prison population
Untried detainees 
(no court decision)”
2009 &
2014
2009: CoE (47) = 274/424
2014: CoE (47) = 315/477
Detainees found 
guilty but no 
sentence yet
Sentenced prisoners 
(appealed or 
can do so)
Detainees with no 
final sentence, but 
serving a prison 
sentence in advance
Sentenced prisoners 
(final sentence), 
of which:
– fine defaulters
– in revocation, 
suspension or 
annulment of the 
conditional release 
or probation
Other cases
Total number of 
prisoners (including 
pre-trial detainees)
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Data and 
Statistics
Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Main offence of 
sentenced prisoners 
(Final Sentence) 
Drug offences
2009 & 
2014
CoE (47) = 88/106
Lengths of 
sentences imposed 
(final sentenced 
prisoners)
Length of the 
sentences by month, 
years or lifetime
2009 CoE (47) = 405/583
2014 CoE (47) = 557/689
Prison population 
(including pre-trial 
detainees): stock
Prison population
Stock – Total
European 
Sourcebook 
of crime 
and criminal 
justice 
statistics,
Université de 
Lausanne
2003-2011
Europe (44) = 387/414
Prison population
Pre-trial detainees
Europe (44) = 356/414
Convicted prison 
population by 
type of offence
Total criminal offences
2006 & 
2010
Europe (44) = 88/92
Drug offences 
(of which %)
2010 Europe (44) = 38/46
Convicted prison 
population in 2010 
Drug offences: Total
2006 & 
2010
Europe (44) = 46/92
Sentenced persons 
held in prisons
Drug Offences
UNODC 2010-2012
Europe (26) = 49/81
Drug Trafficking Europe (26) =36/81
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Table 4 – Cases registered by the police, prosecutors and law courts
Data and 
Statistics
Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Police 
statistics
Crime 
Recorded by 
the Police
Total
Eurostat
1993-2007 Europe (36) = 536/585
Unlawful acts involving 
controlled drugs or precursors
1993-2007 Europe (36) = 486/585
2008-2014 Europe (39) = 275/287
Drug-Related 
Crimes at 
the national 
level, number 
of police-
recorded 
offences
Total
UNODC 2003-2008
Europe (40) = 215/258
Drug Possession Europe (21) = 101/138
Drug Trafficking Europe (37) = 175/240
Police 
Statistics- 
Offences/
Offenders
Offences
Criminal Offences
European 
Sourcebook 
of crime 
and criminal 
justice 
statistics
2003-2011
Europe (42) = 347/387
Drug Offences Europe (42) = 333/387
Drug Trafficking Europe (41) = 269/387
Offenders
Criminal Offenders Europe (42) = 263/396
Drug Offenders Europe (42) = 245/396
Drug Trafficking Europe (42) = 190/396
Conviction 
statistics
Criminal cases 
handled by the 
prosecuting 
authorities 
Output cases: Total
2003-2011
Europe (42) = 218/396
Percentage brought before 
a court of the total output of 
criminal cases handled by the 
prosecuting authorities
Europe (42) = 198/396
Output 
cases by 
offence 
group
Drug Offences
2010
Europe (42) = 33/88
Drug Trafficking Europe (42) = 25/88
Convictions 
Statistics- 
Persons 
convicted
Criminal offences
2003-2011
Europe (42) = 293/369
Drug offences Europe (42) = 272/369
Drug trafficking Europe (42) = 193/369
Total persons 
receiving 
sanctions/
measures
Criminal offences
2006 Europe (41) = 203/473
2010 Europe (41) = 176/602
Drug offences
2006 Europe (41) = 175/473
2010 Europe (41) = 158/602
Drug trafficking
2006 Europe (41) = 113/473
2010 Europe (41) = 104/602
Community 
sanctions and 
measures 
imposed
Criminal offences
2010
Europe (44) = 52/368
Drug offences Europe (44) = 28/368
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Acronyms
Council of Europe (47) = CoE(47): Albania, Andorra, 
Armenia, Austria, Azerbaijan, Belgium, Bosnia-
Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Georgia, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, 
Latvia, Liechtenstein, Lithuania, Luxembourg, 
Malta, Republic of Moldova, Monaco, Montenegro, 
Netherlands, Norway, Poland, Portugal, Romania, 
Russian Federation, San Marino, Serbia, Slovak 
Republic, Slovenia, Spain, Sweden, Switzerland, “The 
former Yugoslav Republic of Macedonia”, Turkey, 
Ukraine, United Kingdom 
European Union (30)= EU(30): Austria, Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, Turkey, United 
Kingdom
Europe (21): Belarus, Bulgaria, Czech Republic, 
Hungary, Poland, Romania, Finland, Iceland, Lithuania, 
Norway, Sweden, United Kingdom, Albania, Croatia, 
Malta, Slovenia, Belgium, France, Liechtenstein, 
Luxembourg, Switzerland
Europe (26): Bulgaria, Czech Republic, Poland, Romania, 
Russian, Denmark, Estonia, Finland, Ireland, Latvia, 
Lithuania, Norway, Sweden, United Kingdom, Andorra, 
Greece, Italy, Malta, Portugal, Serbia, Slovenia, Austria, 
Liechtenstein, Monaco, Netherlands, Switzerland
Europe (31): Austria, Belgium, Bulgaria, Croatia, 
Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, Netherlands, Norway, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, Turkey, United Kingdom
Europe (36): Europe (31) + Liechtenstein, Montenegro, 
TRF-Macedonia, Serbia, Turkey
Europe (37): Europe (21) + Republic of Moldova, 
Russian Federation, Slovakia, Ukraine, Denmark, 
Estonia, Ireland, Bosnia-Herzegovina, Italy, 
Montenegro, Portugal, Serbia, Spain, TRF- Macedonia, 
Germany, Monaco
Europa (39): Europe (36) + Albania, Bosnia-
Herzegovina, Kosovo
Europa (40): Belarus, Bulgaria, Czech Republic, 
Hungary, Poland, Moldova, Romania, Slovakia, 
Ukraine, Denmark, Estonia, Finland, Iceland, Ireland, 
Latvia, Lithuania, Norway, Sweden, United Kingdom, 
Albania, Bosnia-Herzegovina, Croatia, Greece, Italy, 
Malta, Montenegro, Portugal, Serbia, Slovenia, Spain, 
TRF- Macedonia, Austria, Belgium, France, Germany, 
Liechtenstein, Luxembourg, Monaco, Netherlands, 
Switzerland
Europa (41): Europa (42), except Luxembourg
Europe (42): Europa (31) + Albania, Armenia, Bosnia-
Herzegovina, Georgia, Kosovo, Moldova, Russia, Serbia, 
TRF- Macedonia, Turkey, Ukraine
Europe (44): Europe (42) + Azerbaijan, Montenegro
Table references 
Aebi, M. F., Delgrande, N. (2011). SPACE I- Council 
of Europe Annual Penal Statistics. Survey 2009. 
Strasbourg: Council of Europe
Aebi, M. F., Tiago, M. M. & Burkhardt, C. (2015). SPACE I- 
Council of Europe Annual Penal Statistics: Prison popu-
lations. Survey 2014.Strasbourg: Council of Europe
EMCDDA. (2017). http://www.emcdda.europa.eu/
data/stats2015
EMCDDA. (2017). http://www.emcdda.europa.eu/
topics/drug-related-public-expenditure
Eurostat. (2017). http://ec.europa.eu/eurostat/data/
database?node_code=gov_10a_exp
UNODC. (2017). http://www.unodc.org/unodc/en/
data-and-analysis/statistics/crime.html
UNODC. (2017). http://www.unodc.org/unodc/en/
data-and-analysis/statistics/crime.html
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